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                                        Abstract 
 
The utilization of benzodiazepines and antipsychotics amongst senior citizens in 
the community and in long-term care has long been a concern for families and health care 
providers.   The two studies presented in this thesis examined prescription patterns in 
seniors over sixty-five; first over time, then over geographical area.  The use of 
benzodiazepines and antipsychotics remained stable over the three years of the study.   
Within the community, benzodiazepines and antipsychotics were also more prescribed in 
urban than rural areas. The difference in prevalence of benzodiazepine prescriptions in 
long-term care facilities was significant depending on the regional authority, whereas it 
was not significant for antipsychotic prescriptions.  This research into the utilization of 
benzodiazepines and antipsychotics in the province is valuable because it provides a more 
thorough examination into utilization than has been previously undertaken in 
Newfoundland and Labrador.   
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                                    Chapter 1 
Introduction 
 
1.1 BACKGROUND 
Concern has been expressed by both clinicians and researchers regarding the 
prescription patterns of benzodiazepines and antipsychotics to senior citizens living both 
in the community and in long-term care (Smith et al., 2008).  Seniors are living longer 
today than before and this is being facilitated (at least in part) by the advances in 
medicine.  However, these advances have also led to the proliferation of prescription 
drugs in the country.  This phenomenon has been documented for psychoactive drugs in 
all age groups including seniors (Verdoux et al., 2010).  An increase in prescription drugs 
is particularly worrying for seniors due to their advanced age and inherent frailty. This 
has resulted in multiple organizations such as Health Canada and the Canadian Institute 
for Health Information (CIHI) publishing several warnings about the serious negative 
effects that result from the prescription of these drugs to the elderly (Health Canada, 
2012; Government of Canada, 2014; CIHI, 2014).      
A number of studies have been conducted in North America to study the 
epidemiology of the prescription of benzodiazepines and antipsychotics, which comprise 
two classes of psychoactive drugs.  An American study of over 12,000 nursing home 
residents found that of the 13% taking benzodiazepines, 42% had no appropriate 
indication for the prescription (Stevenson et al., 2010).  A Quebec study of 
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pharmaceutical records by Préville et al. (2012) found that of the 2,320 seniors studied, 
48% received a potentially inappropriate prescription of benzodiazepines.   
Chen et al. (2010) found that 30% of American facility-dwelling residents 
received prescriptions for antipsychotics.  Of these, 32% had no appropriate indication for 
receiving their prescription.  In government run long-term care facilities in Canada, 
23.9% of seniors receiving antipsychotics had no appropriate diagnosis to warrant the 
prescription according to the 2017 information released by CIHI.   By comparison, the 
rate for public long-term care facilities in Newfoundland and Labrador has been estimated 
to be 37.5% (CIHI, 2017).     
Seniors constitute a demographic separate from middle-aged adults due to their 
often complex healthcare needs and altered response to medications, the latter due to a 
changing physiology.  On average, seniors require more medical treatment than any other 
segment of the population.  In 2008, Canadians 65 years and over made up 44% of 
healthcare spending but only 14% of the population (CIHI, 2010).  According to the 
Canadian Medical Association (CMA), Canadians over 65 are more likely visit family 
physicians, visit hospitals, and stay on average 1.5 times longer in hospitals per visit than 
non-senior adults.  Additionally, seniors are prescribed significantly more medications 
than younger adults with polypharmacy being an issue.    A Canadian study of 3,132 
community dwelling seniors found that 27% regularly took five or more medications 
concurrently.  Of these, 12% required medical attention for adverse reaction caused by 
their medications in the past twelve months (Reason et al., 2012).  However, few clinical 
drug studies include seniors due to their relatively frail physical condition and the 
increased risk of mortality (Luo et al., 2016).  
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 Importantly, seniors are at higher risk of adverse effects than younger adults 
because of changes in their physiology, leading to altered pharmacokinetics of their 
medications.  These differences cover three major areas: distribution, hepatic metabolism, 
and renal elimination (Ruscin & Linnebur, 2017).  First, because body fat percentage 
increases significantly with age, the elimination half-life of lipophilic drugs tends to 
increase, increasing the amount of drug stored in the fat cells of the body.  Second, 
hepatic metabolism (primarily phase I metabolism) in the elderly can decrease up to 40% 
with age, leading to a build-up of the drug in the system and increasing the risk of adverse 
effects.  For this reason drugs that are metabolized via phase II metabolism or conjugation 
(such as lorazepam and oxazepam) are preferred for the treatment of elderly patients.  
Third, renal elimination of drugs decreases with age in the elderly, also causing the 
buildup of the drug in the system.  The total amount of drug excreted renally varies 
widely depending on the specific agent and should be taken into account when 
prescribing.   
Seniors are more susceptible to adverse drug effects in clinical drug trial studies 
(Luo et al., 2016).  Typically however, patients in the older age groups are excluded from 
clinical trials, therefore we know less about how medications may affect them.   Given 
the high potential for adverse effects and the fact that seniors comprise such a high 
proportion of healthcare spending every year, extreme diligence is required in monitoring 
and inquiring about adverse drug reactions.  One way to improve the monitoring of 
commonly prescribed and high risk medications for seniors is to study their utilization 
patterns both in the community and long-term care settings.    
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1.2 SENIORS IN NEWFOUNDLAND AND LABRADOR 
 Unlike other provinces in Canada with a high proportion of urban residents, 
Newfoundland and Labrador has a large proportion of its citizens living in rural 
communities (Statistics Canada, 2011).  A rural community is defined as having a 
population of less than 1,000 people and a population density of less than 400 people per 
square kilometre (Statistics Canada, 2011).  Using this definition, 41% of 
Newfoundlanders and Labradorians live in rural communities according to the 2011 
census.  Compared to the three other Atlantic provinces, Newfoundland and Labrador has 
the lowest proportion of rural dwelling residents (with New Brunswick, Prince Edward 
Island, and Nova Scotia ranging from 43% to 53%).  The prevalence of rural dwelling is 
still much higher than Ontario where only 14% of the population lives in rural areas 
(Statistics Canada, 2011). 
 Newfoundland and Labrador also has one of the oldest populations in the country.  
According to 2016 data from Stats Canada, 19% of the province’s population is over the 
age of 65 as compared to the national average of 16.8%. Senior citizens in Newfoundland 
and Labrador who receive old age security (OAS) and the guaranteed income supplement 
(GIS) are eligible to have most of their prescription costs covered by the Newfoundland 
and Labrador Prescription Drug Program (NLPDP).  Since approximately 80% of seniors 
use this program, the NLPDP is an important way of monitoring the prescription of drugs 
to seniors (Department of Health and Community Services, 2017). 
Seniors living in long-term care facilities comprise a specific portion of the total 
demographic of seniors, being on average older and in need of more advanced care 
(DHCS, 2017).  Long-term care facilities are provincially operated care homes in 
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Newfoundland and Labrador which can operate at one or more of four levels.  Each level 
increasing from one through four indicates an increase in the needs and requirements of 
residents in that level of care.  For example, residents in facilities with level three and 
level four care require ongoing supervision from medical staff due to their advanced and 
complex needs(Western Health, 2016).  There are currently 37 long-term care facilities in 
the province that are run by the provincial Department of Health and Community 
Services of which 19 are in Eastern Health, 11 are in Central Health, four are in Western 
Health, and three are in Labrador-Grenfell Health (DHCS, 2017). 
 
 
1.3 BENZODIAZEPINE USE IN SENIORS  
1.3.1 Overview of Benzodiazepines 
Benzodiazepines are a group of drugs designed to suppress the nervous system 
and are officially indicated by Health Canada for use to treat a number of conditions such 
as anxiety and panic disorders, insomnia, seizures, muscle spasms, alcohol withdrawal, 
and to sedate hospital patients prior to surgery (CPhA, 2017; Bandelow et al., 2014; 
Schutte-Rodin et al., 2008).  Benzodiazepines also continue to be used without Health 
Canada approval to treat other conditions such as agitation, restless leg syndrome, 
obsessive compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) (van 
Ameringen et al., 2014; Mellman et al., 2002).    
Benzodiazepines are classified as depressants, which affect the central nervous 
system of the body via the neurotransmitter gamma-aminobutyric acid (GABA) 
(Government of Canada, 2014).  Benzodiazepines were originally developed in 1955 and 
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first introduced in 1960 as an anti-anxiety medication, or anxiolytic.  They were 
introduced to the market in order to replace another anxiolytic group of drugs, the 
barbiturates, due to the latter’s high risk of death when taken in overdose.  Beginning in 
the 1970s, the prescription of benzodiazepines became widespread.  For a list of 
benzodiazepines prescribed in Canada, please see Table 1.1.    
      
1.3.2 Epidemiology of Benzodiazepine Use in Canada  
 One of the first studies of the utilization of benzodiazepines in Canada was 
performed by Busto et al. (1989).  The study involved patients admitted to the Clinical 
Institute of the Addiction Research Foundation in Toronto for the years between 1978 and 
1987.  According to the authors, the utilization of benzodiazepines remained steady for 
the first five years at 33 standard units per 1,000 people per day but after 1983 steadily 
increased reaching 48 units per 1,000 people per day by 1987.   
 In more recent years, use of benzodiazepines in community dwelling seniors has 
decreased from the rates seen in previous decades.   A Quebec study by Egan et al. (2000) 
studying 1,423 seniors for a 180 day period found a 19.8% prevalence of benzodiazepine 
use.  A similar study in Ontario followed over one million seniors for five years from 
1993 to 1998.  It was found that prevalence of seniors receiving benzodiazepines 
decreased over time from 25.1% to 22.5% (Tu et al., 2001).  Finally, a study from 
Manitoba analyzed the cross sectional data of between 154,890 and176,498 seniors for a 
sixteen year period from 1996 to 2012 (Alessi-Severini et al., 2014).   
 A lesser degree of research has been done on the prevalence of benzodiazepine 
research in long-term care facilities, however difference across the country become 
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apparent.  An Ontario retrospective cohort study of 57,504 residents living in long-term 
care found that 38% percent of new entrants to long-term care received at least one 
benzodiazepine prescription (Bronskill et al., 2013).  Of these, 49% were given at least a 
further two prescriptions in a twelve month period, totalling at least 100 pills.  A study 
from Alberta (Hagen et al., 2015) examined the records of 2,443 long-term care residents 
for a twelve month period.  These residents lived in 24 different facilities (ten urban and 
fourteen rural) and it was found that the prevalence of benzodiazepine prescription in the 
urban facilities was higher than in the rural facilities (15.7% versus 7.6%).          
Research has also been conducted to measure the strength of the dose 
administered to seniors in Canada.  Bartlett et al. (2004) followed 78,367 community 
dwelling seniors in Quebec for five years from 1989 to 1994.  The authors found that the 
average uninterrupted usage of benzodiazepines was 75.5 days and that the seniors in the 
study received on average approximately half of the dosage usually recommended for 
adults.  
 Not all provinces, however, are experiencing a decrease in benzodiazepine use.  
As mentioned earlier in this paper, Newfoundland and Labrador has the highest 
proportion of seniors in Canada.  A report commissioned in 2003 by the Newfoundland 
and Labrador Centre for Applied Health Research (NLCAHR) describes prescription drug 
use in Newfoundland and Labrador for 1999 including benzodiazepines (NLCAHR, 
2003).  It was found that benzodiazepines were in the top five drug classes prescribed to 
people in the province, making up 7.6% of total prescriptions.  Lorazepam was also in the 
top ten individual agents prescribed, making up 1.8% of total prescriptions.  Finally, 
benzodiazepine prescription was highest in the Western Health Regional Health Authority 
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(RHA), followed by the Eastern and Central Health authorities.  While the report 
specifies the use of benzodiazepines by health region, it does not distinguish between 
urban and rural areas, nor does it capture changes over time.  In addition, there is no 
information provided about dosage of the drugs in question.  
The other Atlantic provinces display a similar demographic distribution to 
Newfoundland and Labrador (Statistics Canada, 2016); that is they have a higher 
percentage of both senior citizens and total residents living in rural areas.  This may 
contribute to a difference observed in the trend of benzodiazepine use in this area.  Smith 
et al. (2008) found that the prevalence of seniors in Nova Scotia receiving 
benzodiazepines increased from 123 DDDs per 1,000 people per day in 2000 to 138 
DDDs per 1,000 people per day in 2003. 
 
1.3.3 Adverse Effects of Benzodiazepines 
More common adverse effects of benzodiazepines include dizziness, drowsiness 
and fatigue, muscle weakness, and slowed reaction times.  Less common but more severe 
side effects include heart palpitations, racing heart beat (tachycardia), memory 
impairment, depression, muscle spasms, and seizures.  Alcohol should be avoided while 
taking benzodiazepines as both depress the central nervous system and can cause loss of 
consciousness, respiratory failure, and death if used together (Canadian Pharmacists 
Association, 2017).  While the sedative effects of benzodiazepines can cause a person to 
fall asleep, prolonged use has been demonstrated to worsen overall sleep quality (Poyares 
et al., 2004).   
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As previously mentioned, seniors have proven to be more susceptible to all 
adverse effects of medications including benzodiazepines. Symptoms of benzodiazepine 
use consistently recorded in seniors include cognitive impairment (Bogunovic & 
Greenfield, 2004), falls and fractures (van Strien et al., 2013), motor vehicle accidents 
(Thomas, 1998), and delirium (Alagiakrishnan & Wiens, 2004).  
 A concern for the long-term use of benzodiazepines is dependency.  Dependency 
usually occurs only when benzodiazepine use significantly exceeds the recommended two 
to four weeks prescription (Greenblatt & Shader, 1978).  Dependency can either be 
physical or psychological, the distinction being that physical dependence provokes 
“objective changes” in physiology while psychological dependence creates strong 
cravings but no physical symptoms.  Dependency is usually associated with an increased 
tolerance of the drug requiring an increasing dose, thereby proportionally increasing the 
risk of adverse effects (Greenblatt & Shader, 1978).   
Use of short-acting benzodiazepines such as lorazepam (Ativan), as opposed to 
long-acting benzodiazepines, have been shown to significantly decrease the time it takes 
to develop either physical or psychological dependence (Nelson & Chouinard, 1999).  
Discontinuation of benzodiazepines after long-term use may result in withdrawal 
symptoms.  These may include recurrence of symptoms that caused the prescription of 
benzodiazepines in the first place such as insomnia, anxiety and panic attacks, as well as 
headaches and muscle stiffness.  Abrupt discontinuation of benzodiazepine treatment can 
lead to severe reactions such as seizures, delirium tremens, and coma (Péturrson, 1994).   
 Despite the seeming lack of consistency there are in fact guidelines for the 
prescription of benzodiazepines that have been in place for some time.  The World Health 
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Organization (WHO, 1996) published an extensive document that explained in detail the 
precautions that should be taken when prescribing benzodiazepines (WHO, 1996).  
Within Canada, provincial medical associations have also issued their own guidelines 
(CPSA, 2015).  Based on evidence gathered, Choosing Wisely Canada has also issued 
recommendations to not use benzodiazepines in seniors as first line therapies for 
insomnia, agitation, or delirium (CWC, 2017). The Canadian Deprescribing Network has 
also published guidelines to assess appropriateness of benzodiazepine use and has 
algorithms to aid in reducing the dose or stopping their use (Canadian Deprescribing 
Network, 2016). 
 
 
1.4 ANTIPSYCOTIC USE IN SENIORS 
1.4.1 Overview of Antipsychotics  
Antipsychotics are a class of medication used to treat psychosis, a severe mental 
disorder in which thoughts and emotions become impaired to the point that contact is lost 
with external reality.  These medications are officially recommended by Health Canada 
for the treatment of schizophrenia and related disorders, as well as psychotic symptoms in 
bipolar disorder.  Antipsychotics can also be used to treat severe non-responsive cases of 
major depressive disorder and Tourette’s syndrome (CAMH, 2012).  Antipsychotics are 
used off label to treat a host of other psychiatric conditions including obsessive-
compulsive disorder, post-traumatic stress disorder, anorexia, and insomnia (Baylor 
College of Medicine, 2012).   
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Health Canada currently has a black box warning in place for antipsychotic 
prescription to seniors with dementia, indicating that their use is associated with a 
significantly increased risk of death (Health Canada, 2012).  Risperidone (brand name 
Risperdal) is the only antipsychotic officially indicated by Health Canada to treat severe 
and acute dementia-related agitation and aggression in seniors and is approved for short-
term use only (Health Canada, 2012).  Despite this, antipsychotic prescription has become 
increasingly common in the treatment of seniors with other behavioural issues stemming 
from dementia such as wandering or calling out, neither of which are appropriate 
symptoms warranting treatment with antipsychotics.  This trend should be of concern to 
policy makers as seniors are at a higher risk than the general population of serious 
adverse effects from antipsychotic use (Jašović-Gašić et al., 2012).  
Antipsychotics were discovered and subsequently came into use starting in the 
1950s.  This group of drugs were later referred to as first generation or typical 
antipsychotics.  It was discovered early on that typical antipsychotics caused a variety of 
adverse effects including severe movement disorders including muscle spasms, rigidity, 
and tremors.  Collectively, these disorders are referred to as extrapyramidal symptoms 
(EPS) (Meyer & Simpson, 1997).  Researchers soon began to search for an alternative to 
the medications that were causing such severe and debilitating adverse effects.  Clinical 
testing began for what was supposed to be an alternative to the typical antipsychotic, the 
second generation or atypical antipsychotic.  In 1990, the first atypical antipsychotic 
(clozapine) was approved by the FDA for general use in the United States.  Since that 
time, the prescription and number of atypical antipsychotic agents has increased 
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dramatically due at least in part to the purportedly decreased risk of EPS that they offer 
(Shen, 1999). For a list of antipsychotics prescribed in Canada, please see Table 1.2.  
 
1.4.2 Epidemiology of Antipsychotic Use in Canada 
The rate of antipsychotic prescription in long-term care facilities across Canada 
has been repeatedly been identified as a serious problem.  Though national utilization 
rates have dropped from 32% to 24% in the past four years, there is still work to be done.  
Nearly a quarter (23.9%) of Canadian seniors in long-term care for the 2015-2016 year 
were receiving antipsychotics with no appropriate diagnosis to warrant their use (CIHI, 
2017).  Antipsychotic prescriptions have been linked in the literature to a number of 
demographic factors including female sex, older age, and lower income (Sivanthan et al., 
2015).  In the long-term care setting, behavioural problems, conflicts with staff members 
and family, as well as social isolation were also all significantly correlated with the 
prescription of antipsychotics (Foebel et al., 2015).   
 A study by Hagen et al. (2006) examined two Canadian long-term care facilities 
(N=289) where residents in one facility (N=178) moved facilities and residents in the 
other (N=111) remained.  Prevalence of antipsychotic prescriptions was measured in both 
facilities before, during, and after the move for one set of residents.  Prevalence of 
antipsychotic use remained relatively stable in the “remain” facility (between 30.3% and 
33.1%, p=0.88).  On the other hand, prevalence in the “move” facility rose at every 
measure from 21.5% to 32.6% to 36.9% (p=0.002).   
An Ontario study by Rochon et al. (2007) collected data on 47,322 residents from 
485 different provincially regulated facilities during the month of December 2003.  The 
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authors organized these facilities into quintiles according the prevalence of antipsychotic 
prescription.  Out of the total number of residents, 15,317 (32.4%) received 
antipsychotics.  The average within the quintiles ranged from 20.9% to 44.3% indicating 
a significant difference (p>0.005).  These studies are troubling given the serious adverse 
effects that can occur when seniors are prescribed antipsychotics without careful 
consideration.     
 
1.4.3 Adverse Effects of Antipsychotics   
Both typical and atypical antipsychotics have been associated with serious adverse 
effects.  However, since the two generations differ significantly from each other the 
adverse effects are also different.  More common adverse effects of typical antipsychotics 
include a lengthening of the QT interval which increases the risk of an irregular heartbeat.  
Other common adverse effects include dry mouth, constipation and urinary retention, 
weight gain, hyperglycemia and sexual dysfunction (Muench & Hamer, 2010).  Less 
common adverse effects of typical antipsychotics include blurred vision, rashes, alopecia, 
nausea and vomiting, jaundice, and hypertension.  More serious effects include 
tachycardia, cardiac arrest and sudden cardiac death.  The most noticeable of adverse 
effects from typical antipsychotics are EPS that affect the central nervous systems.  
Common types of EPS are muscle spasms (dystonia), motor restlessness (akathesia), 
muscle rigidity (parkinsonism), and jerky, irregular motions (tardive dyskinesia) 
(Beaumont, 2000).   A major concern with typical antipsychotics is neuroleptic malignant 
syndrome (NMS), a potentially fatal condition which causes muscle rigidity, fever, 
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fluctuating blood pressure and pulse as well as changing levels of consciousness (CPhA, 
2017).   
Atypical antipsychotics were developed specifically to decrease the risk of EPS 
but other adverse effects are still a risk in those taking them, particularly seniors.  
Common adverse effects when taking atypical antipsychotics include dry mouth, 
constipation and urinary retention, hypotension, seizures, sedation and weight gain.  Less 
common adverse effects include a prolonged QT interval and an increased risk of type 2 
diabetes (Muench & Hamer, 2010).  Atypical antipsychotic use amongst both community 
and facility dwelling seniors has also been shown to significantly increase the risk of 
potentially fatal pneumonia (Stephenson, 2010).  Interestingly enough, studies comparing 
typical and atypical antipsychotics have shown that although atypicals show a 
significantly reduced risk of extrapyramidal symptoms in seniors, the risk of falls in 
seniors does not significantly decrease (Hien et al, 2005).     
 Choosing Wisely Canada has recently released a toolkit to aid long-term care 
facilities in the proper and effective use of antipsychotics (CWC, 2017).  The toolkit 
includes several suggestions to reduce antipsychotic prescriptions: 1) Create an 
interdisciplinary team of professionals to review residents who are receiving 
antipsychotics, 2) Agree on which symptoms require antipsychotic prescription (e.g. 
psychotic symptoms, physical aggression), and which do not (wandering, insomnia), 3) 
Whenever possible prescribe only one antipsychotic and in the lowest effective dose, 
tapering the dose off as quickly as possible, and 4) Train facility staff to recognize factors 
that may be causing certain behaviours in seniors (e.g. tiredness, depression, stress) and 
find ways to solve these problems without pharmacological intervention.   
 15 
 
1.5 STUDY OBJECTIVES 
This thesis will address a gap in the knowledge concerning the way 
benzodiazepines and antipsychotics are prescribed in Newfoundland and Labrador.  This 
thesis can be described by a primary research question: What are the patterns of use over 
time and across geographic regions for antipsychotics and benzodiazepines in senior 
citizens living in long-term care and the community in Newfoundland and Labrador?  In 
order to implement an effective intervention, it is critical to first have an accurate and 
detailed understanding of the current utilization of benzodiazepines and antipsychotics in 
the province. The thesis objectives will be accomplished by conducting two different 
studies, each of which address specific aspects of drug utilization.   
  The first study will examine patterns of utilization for benzodiazepines and 
antipsychotics over a period of three years from 2011 to 2014.  The objective of this study 
is to answer the following question: What differences appear, if any, when utilization of 
benzodiazepine and antipsychotic prescriptions are studied over time in community and 
facility dwelling seniors in the province? It will describe patterns for both community and 
long-term care dwelling seniors who are eligible for public drug insurance in the 
province.   
The second study will compare variations of utilization of antipsychotic and 
benzodiazepine medications as they occur depending on geographic location.  The 
objective of this study is to answer the following question: What patterns appear when 
comparing utilization of benzodiazepine and antipsychotic prescriptions across 
geographic areas?  Community dwelling seniors will be compared on the basis of whether 
they live in an urban or rural area.  Residents living in long-term care facilities will be 
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categorized by the regional health authority (RHA) in which they reside, as well as at the 
facility level.      
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Table 1.1: List of Benzodiazepine Agents with Common Doses and Half Lives  
 
 
 
*Common doses taken from WHO website (WHO, 2016) 
**Half-life information taken from RxTx website (RxTx, 2018) 
 
  
LA=long acting 
IA=intermediate acting 
SA=short acting 
 
N.B.: Half-life may vary significantly depending on age of the patient as well as the route 
of administration (oral versus injection) 
 
 
 
 
 
  
Sub Class Agent  Common Dose* Half Life** 
    
Anticonvulsant Clonazepam  8 mg 20-50 hrs (LA) 
    
Anxiolytics Diazepam 10 mg 20-100 hrs (LA) 
 Chlordiazepoxide 30 mg 30-100 hrs (LA) 
 Oxazepam 50 mg 5-15 hrs (SA) 
 Potassium Clorazepate 20 mg 20-100 hrs (LA) 
 Lorazepam 2.5 mg 10-20 hrs (IA) 
 Bromazepam 10 mg 12-20 hrs (IA) 
 Clobazam 20 mg 71-82 hrs (LA) 
 Alprazolam 1 mg 6-26 hrs (SA) 
    
Sedative/Hypnotics Flurazepam 30 mg 40-100 hrs (LA) 
 Nitrazepam 5 mg 16-38 hrs (IA) 
 Triazolam 0.25 mg 2-5 hrs (SA) 
 Temazepam 20 mg 10-20 hrs (IA) 
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Table 1.2: List of Antipsychotic Agents with Common Doses and Half Lives  
 
 
 
 
*Common doses taken from WHO website (WHO, 2016) 
**Half-life information taken from RxTx website (RxTx, 2018) 
  
 
N.B.: Half-life may vary significantly depending on age of the patient as well as the route 
of administration (oral versus injection) 
 
   
 
 
  
Sub Class Agent Common Dose* Half Life** 
    
Typical Chlorpromazine  300 mg ~30 hrs  
 Levomepromazine  300 mg ~20 hrs  
 Perphenazine  30 mg 8-12 hrs  
 Prochlorperazine  100 mg 4-8 hrs  
 Trifluoperazine  20 mg 10-20 hrs  
 Periciazine  50 mg ~12 hrs  
 Haloperidol  8 mg 14-36 hrs 
 Flupentixol  6 mg ~35 hrs 
 Zuclopenthixol  30 mg ~20 hrs 
    
Atypical Ziprasidone  80 mg 7-10 hrs 
 Clozapine  300 mg 6-26 hrs 
 Olanzapine  10 mg 30-60 hrs 
 Quetiapine  400 mg 7-12 hrs 
 Risperidone  5 mg ~20 hrs 
 Aripiprazole  15 mg ~75 hrs 
 34 
 
Chapter 2 
Time-trends in the Utilization of Antipsychotic and Benzodiazepine 
Prescribing in Newfoundland and Labrador 
 
2.1 INTRODUCTION 
2.1.1 Background 
 Seniors constitute one of the most vulnerable demographics in our society due to 
factors such as higher rates of serious chronic disease, loss of independence, and lower 
incomes.  The utilization of both benzodiazepines and antipsychotics has come under 
scrutiny in Canada and in other parts of the world, particularly for their use in the senior 
population and potential for adverse effects.  Both benzodiazepines and antipsychotics are 
listed as potentially inappropriate medication classes in the updated Beer’s list and 
STOPP/START criteria, as they increase the risk of serious side effects in seniors 
(American Geriatrics Society, 2015; Pharmacist’s Letter/Prescriber’s Letter, 2011).  
Specifically, benzodiazepines increase the risk of cognitive impairments (Edelstein et al., 
2014), falls and fractures (Smith et al., 2008), delirium (Alagiakrishnan & Wiens, 2004), 
and motor vehicle accidents (Thomas, 1998).  Moreover, benzodiazepine users often 
develop dependence (Cunningham et al., 2010) and the risk of side effects may be 
exacerbated when the drugs are taken long-term (Huybrechts et al., 2011; Bartlett et al., 
2009).  Similarly, seniors are sensitive to the adverse effects of antipsychotics, which 
increase the risks of cerebrovascular events (Vasilyeva et al., 2013), hip fractures (Pratt et 
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al., 2012), bacterial infections (Huybrechts et al., 2012), and all-cause mortality (Verdoux 
et al., 2010).   
 Despite the documented side effects, the proportion of seniors in the general 
population taking psychoactive medications over the last few decades has increased in the 
developed world (Verdoux et al., 2010; Smith et al., 2008).  Benzodiazepines and 
antipsychotics continue to be used in both the community and long-term care settings in 
Canada’s senior population.  Benzodiazepines and antipsychotics are most prevalent in 
long-term care facilities where they are often used as the cheapest and most efficient way 
to manage behavioural issues in residents (Jašović-Gašić et al., 2012).     
According to Canadian Institute for Health Information (CIHI) research in five 
different provinces, benzodiazepines and antipsychotics are used by approximately 22% 
and 5% respectively of seniors in the community (CIHI, 2012).   In long-term care, a 
major concern is the use of antipsychotics which was reported to be on average 39% 
nationwide in 2014 (CIHI, 2016).  CIHI estimates that 37.5% of seniors living in 
Newfoundland and Labrador who are receiving antipsychotic medication have not been 
diagnosed with psychosis, the main indication for its use.  This is in comparison with the 
Canadian average of 23.9% (CIHI, 2017).  
 
2.1.2 Purpose of Study and Objectives 
To further understand the trends of use over time at a population level, this study 
investigated the utilization of benzodiazepines and antipsychotics among senior citizens 
using public drug coverage in Newfoundland and Labrador.  
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2.2 METHODS 
2.2.1 Population and Inclusion/Exclusion Criteria 
The population for this study comprised all senior citizens age 65 years and older 
living in Newfoundland and Labrador (NL) who received publically funded drug 
coverage between April 1
st
, 2011 and March 31
st
, 2014 under the provincial prescription 
drug program (NLPDP).  Individuals were categorized as either living in the community 
or in long-term care facilities.  For the long-term care setting, only facilities funded by the 
province were included in the analysis.  Individuals were excluded from the study if they 
spent longer than 7 days outside long term care facilities while being transferred, if their 
demographic information was missing, or if their registered postal code was from outside 
the province.  This project has been approved by the Health Research Ethics Board 
(HREB #2016.324). 
 
2.2.2 Data Sources  
All data linkages were performed at the Newfoundland and Labrador Centre for 
Health Information (NLCHI) and data was de-identified before being released.  Data 
linkage was required to amalgamate information from the following three databases: 
1) The Provincial Client Registry, which contains personal demographic 
information such as Medical Care Plan (MCP) number, sex, month and year of 
birth, and postal code. 
2) The Newfoundland and Labrador Prescription Drug Plan (NLPDP) database, 
containing prescription records for individuals who receive Old Age Security 
(OAS) benefits and the Guaranteed Income Supplement (GIS) (Department of 
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Health and Community Services, 2017).  Approximately 80% of the total 
populations of seniors 65 years and older in the province are eligible for 
NLPDP coverage.  The NLPDP claims database contains typical 
administrative prescription data such as the drug dispensed, date of 
dispensation, drug dosage, quantity dispensed, and days’ supply.  
Benzodiazepines and antipsychotics studied were identified by their 
Anatomical Therapeutic Chemical (ATC) code (for example, all ATC codes 
for psychoactive medications begin the letter N) (See Appendices 4.1 and 4.2).  
3) The Long-Term Care (LTC) Module of the Provincial Meditech database 
which contains a list of seniors living in long-term care facilities along with 
admission and discharge dates. 
  
2.2.3 Measuring Drug Utilization 
Three different methods were used to measure drug utilization over time for 
seniors living in Newfoundland and Labrador.  In addition, the prescription of each 
individual agent was analyzed to determine any patterns in terms of use.  The three 
methods applied for this analysis were as follows:    
1) The prevalence of benzodiazepines, antipsychotics, and concurrent use of both 
drug classes was calculated as the ratio of the total number of users per quarter 
for each drug class of interest to the total number of NLPDP beneficiaries per 
quarter.  The primary definition of a benzodiazepine or antipsychotic user was 
an individual dispensed two or more prescriptions per quarter for the drug of 
interest.   
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2) The rate of prescription records per 1,000 was calculated by the ratio of the 
total number of benzodiazepine or antipsychotic prescriptions to the total 
number of prescriptions per quarter.  Only paid prescription claims were 
included in the calculations.   
3) To account for differences in drug quantities and doses the total number of 
defined daily doses (DDDs) per quarter per drug was calculated.  A DDD is 
defined by the World Health Organization (WHO) as the “assumed average 
dose per day of a drug in adults, as prescribed for its main indication” (WHO 
Collaborating Centre for Drug Statistics Methodology, 2009).  The total DDD 
measures the relative volume of each prescription and is calculated by 
multiplying the strength of the dose by the number of days’ supply and 
dividing by one DDD.  DDD is commonly reported as DDD per 1,000 persons 
per day, this measurement taking into account the length of the prescription in 
days. 
 
2.2.4 Statistical Analysis  
All analyses were conducted separately for seniors living in the community and 
those in long-term care facilities.  Mean and standard deviation as well as number and 
frequency were used to summarize the study population for continuous and categorical 
variables respectively.   Due to the longitudinal nature of the study, each of the patients 
was measured repeatedly during the study period with the units of comparison being 
quarters.   These measurements are therefore not independent from each other, which 
violates the assumption of independence.   This correlation is addressed by the 
 39 
 
Generalized Estimating Equation (GEE) technique.  Appropriate link functions were used 
for prevalence by person (logit link function), rate of prescription (log link function), and 
volume of prescription (identify link function).    Age, sex, and chronic disease score 
were included as covariates in each model.  The chronic disease score (CDS) is a 
prescription based comorbidity score whereby individuals are given one point per drug 
class up to a total of 24 points.  A higher chronic disease score is associated with an 
increased risk of one year all-cause hospitalization and mortality (Lix et al., 2016).  An 
autoregressive autocorrelation structure was used for all GEE models. All models were 
tested for usual assumptions such as linearity and homoscedasticity with no violations 
being found.  As with other methods, results are considered statistically significant if the 
p-value is less than 0.05.  
A series of additional analyses were conducted to test the robustness of the results 
on the definition of drug users. Specifically, a distinction was made between two types of 
drug user: 1) Those receiving at least two prescriptions per quarter, and 2) “Chronic drug 
users” defined as those receiving two or more prescriptions per quarter for two or more 
quarters.  All statistical analyses were conducted using SPSS, version 23. 
 
 
2.3 RESULTS 
2.3.1 Overview   
 Out of the original 53,746 seniors in the database, a total of 1,028 seniors were 
excluded from the analysis.  There were a total of 4,966,944 prescriptions dispensed to 
52,718 individuals within the study period. Of these, 49,875 (94.6%) lived in the 
 40 
 
community and were dispensed 4,579,704 prescriptions.  The median age for seniors in 
the community was 73 years, 43% of them were male, median CDS was four (Table 2.1). 
Each senior received on average nine prescriptions per quarter for an average of ten 
quarters.  There were 2,843 (5.4%) seniors within long-term care facilities who were 
dispensed a total of 388,240 (7.8%) prescriptions.  The median age for seniors in long-
term care was 84 years, 31% were male, median CDS was five (Table 2.2).  Each senior 
received on average 24 prescriptions per quarter for an average of six quarters.  The 
majority of prescriptions for both drug classes in were issued for one month in the 
community and in long-term care (See Appendices 2.1-2.4).   
 
2.3.2 Benzodiazepine Prescriptions in the Community 
In the community 15,455 of the 49,875 seniors (31.0%) in the database received at 
least one prescription for benzodiazepines within the three year period. Despite being 
statistically significant (p<0.001), there was minimal change over time (OR=0.990; 
95%CI=0.987,0.992).  There were a total of 221,405 benzodiazepine prescriptions 
written, and 10,665 seniors (21.4%) received two or more benzodiazepine prescriptions 
per quarter (Table 2.3).  The median age for seniors taking benzodiazepines was 74 years 
and males made up 3,467 (or 32.5%) of seniors.  Over the series of twelve quarters, 
between 20.8% and 22.4% of seniors were prescribed two or more benzodiazepines per 
quarter (Figure 2.1).  Of these, each senior received on average three prescriptions for 
benzodiazepines per quarter for an average of seven quarters out of twelve.  Of the total 
number of seniors in the community, 7,863 (15.8%) were chronic benzodiazepine users.  
The prescribing rate for benzodiazepines in the community ranged from 47 to 49 with an 
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average of 48 prescriptions per 1,000 total prescriptions (Figure 2.2) and there was 
minimal change over time (p=0.09).  The total number of DDDs for benzodiazepine 
prescriptions was 5,521,747.   The number of DDDs/1,000 people/day over the twelve 
quarters was between 130 and 135 with an average of 132 (Figure 2.3).  Despite being 
statistically significant (p<0.001), there was minimal change in the DDD scores of 
benzodiazepine prescriptions over time (B=-0.166, 95CI=-0.210,-0.121).    
 Table 2.3 reports the use of individual benzodiazepine agents in the community. 
The intermediate-acting benzodiazepine lorazepam was the most commonly prescribed of 
the individual agents (5,932 seniors or an average of 55.6%), followed by temazepam 
(2,153 seniors or an average of 20.2%) (Appendix 1.1).  The most commonly prescribed 
short-acting benzodiazepine was oxazepam, being prescribed to 1,047 seniors (or an 
average of 9.8%).  For lorazepam, the total DDD over the three year period was 
1,870,196.  The DDDs/1,000 people/day over the twelve quarters was between 51 and 55 
with an average score of 52 (Appendix 1.2).   For temazepam, the total DDD over the 
three year period was 1,425,386.  The DDDs/1,000 people/day over the twelve quarters 
was between 27 and 30 with an average score of 29.   For oxazepam, the total DDD over 
the three year period was 253,373.  The DDDs/1,000 people/day over the twelve quarters 
was between seven and nine with an average score of eight.   
 
2.3.3 Benzodiazepine Prescriptions in Long-Term Care   
In long-term care 1,486 of the 2,843 seniors (52.2%) in the database received a 
prescription for benzodiazepines within the three year period.  There was no significant 
change in prevalence over time (p=0.198).  There were a total of 17,301 benzodiazepine 
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prescriptions written, and 1,046 seniors (36.8%) received two or more benzodiazepines 
per quarter (Table 2.4).  Of the 1,046 seniors, males made up 304 (29.1%) and the median 
age was 83 years.  Over the series of twelve quarters between 30.3% and 39.4% received 
two or more benzodiazepine prescriptions per quarter (See Figure 2.4).  On average each 
senior received four prescriptions for benzodiazepines per quarter for four consecutive 
quarters.  Finally, of the total number of seniors in long-term care, 743 (26.1%) were 
chronic benzodiazepine users.  The prescribing rate for benzodiazepines in long-term care 
was between 42 and 47 with an average of 45 per thousand total prescriptions (Figure 2.5) 
and was stable over time (p=0.296).  The total number of DDDs for benzodiazepine 
prescriptions was 398,971.   The number of DDDs/1,000 people/day over the twelve 
quarters was between 160 and 207 and was stable over time (p=0.923) with an average 
DDD score of 192 (Figure 2.6). 
 Similar to the community, lorazepam was the most commonly prescribed of the 
individual agents (760 seniors or 72.7%), followed by temazepam (207 seniors or 19.8%) 
taking benzodiazepines twice or more per quarter (Appendix 1.5).  The most commonly 
prescribed short-acting benzodiazepine was oxazepam, being prescribed to 121 seniors or 
11.6% of those taking benzodiazepines (Table 2.4).  For lorazepam, the total DDD over 
the three year period was 161,775.  The DDDs/1,000 people/day over the twelve quarters 
was between 92 and 119 with an average score of 111 (Appendix 1.6).  For temazepam, 
the total DDD over the three year period was 125,987.  The DDDs/1,000 people/day over 
the twelve quarters was between 39 and 53 with an average score of 48.  For oxazepam, 
the total DDD over the three year period was 25,217.  The DDDs/1,000 people/day over 
the twelve quarters was between ten and twenty-two with an average score of fifteen.   
 43 
 
2.3.4 Antipsychotic Prescriptions in the Community 
In the community 3,066 of the 49,875 seniors (6.1%) in the database received a 
prescription for antipsychotics within the three year period.  Despite being statistically 
significant (p<0.001), there was minimal change over time (OR=0.984; 
95%CI=0.978,0.989). There were a total of 57,136 antipsychotic prescriptions written, of 
which 2,321 of seniors (4.7%) received two or more antipsychotics per quarter (Table 
2.3).  The median age for seniors taking antipsychotics was 76 years and 912 (of 39.3%) 
were male.  Over the series of twelve quarters, between 4.4% and 5.0% of seniors were 
prescribed two or more antipsychotics per quarter (See Figure 2.1).  On average each 
senior received four antipsychotic prescriptions per quarter for five consecutive quarters.  
Finally, of the total number of seniors in the community, 1,851 (3.7%) were chronic 
antipsychotic users. The prescribing rate for antipsychotics ranged between twelve  and 
thirteen with an average of twelve prescriptions per 1,000 total prescriptions (Figure 2.2), 
which remained stable over time (p=0.320).  The total number of DDDs for antipsychotic 
prescriptions was 442,248.  The DDDs/1,000 people/day over the twelve quarters was 
between twelve and thirteen with an average of thirteen (Figure 2.3).  Despite being 
statistically significant (p=0.001), there was minimal change in the DDDs of 
antipsychotic prescriptions over time (B=-0.147, 95CI=-0.236,-0.058).    
  Table 2.3 reports the use of individual antipsychotic agents in the community. The 
atypical antipsychotic quetiapine was the most commonly prescribed of the individual 
agents (1,455 seniors or 62.7% of antipsychotic users), followed by risperidone (611 
seniors or 26.3% of antipsychotic users) (Appendix 1.3). For quetiapine, the total DDD 
over the three year period was 206,006.  The DDDs/1,000 people/day over twelve 
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quarters was between two and three with an average score of two (Appendix 1.4).  For 
risperidone, the total DDD over the three year period was 86,002.  The DDDs/1,000 
people/day over twelve quarters remained at a score of one.   
 
2.3.5 Antipsychotic Prescriptions in Long-Term Care  
 In long-term care, 1,273 of the 2,843 seniors (44.8%) in the database received a 
prescription for antipsychotics within the three year period, which remained stable over 
time (p=0.342).  There were a total of 21,495 antipsychotic prescriptions written, of 
which 1,134 seniors (39.9%) received two or more antipsychotic prescriptions per quarter 
(Table 2.4).  The median age for seniors taking antipsychotics was 83 years and 394 (or 
34.7%) were male.  Over the series of twelve quarters, between 34.3% and 42.2 % of 
seniors were prescribed two or more antipsychotics per quarter with an average of 39.9% 
(See Figure 2.4).  Finally, of the total number of seniors in long-term care, 903 (31.8%) 
were chronic antipsychotic users. The prescribing rate for antipsychotics was between 53 
and 62 with an average of 55 per 1000 total prescriptions (Figure 2.5), which remained 
stable over time (p=0.898).  The total number of DDDs for antipsychotic prescriptions 
was 127,778.   The DDDs/1,000 people/day was stable over the twelve quarters (p=0.688) 
at between 40 and 52 with an average score of 46. 
  As in the community, quetiapine was most commonly prescribed of the individual 
agents in long-term care and was received by 797 seniors (70.3% of antipsychotic users) 
taking antipsychotics twice or more per quarter (Appendix 1.7).  The other commonly 
prescribed agent was the atypical antipsychotic risperidone, being prescribed to 342 
seniors (30.2% of users).  For quetiapine, the total DDD over the three year period was 
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90,563.  The DDDs/1,000 people/day over the twelve quarters was between 18 and 26 
with an average score of 23 (Appendix 1.8).  For risperidone, the total DDD over the 
three year period was 37,503.  The DDDs/1,000 people/day over the twelve quarters was 
between eight and thirteen with an average score of ten.   
 
2.3.6 Combined Utilization of Benzodiazepines and Antipsychotics 
There were 1,173 out of 49,875 seniors (2.4%) living in the community who 
received two or more benzodiazepine and antipsychotic prescriptions per quarter in the 
same quarter.  Of the 1,173 seniors, males made up 412 (35.1%) of the population and the 
median age was 74 years.  Over the series of twelve quarters between 2.2% and 2.6% of 
seniors were chronic users of both benzodiazepines and antipsychotics (Figure 2.1).  
These seniors received an average of three benzodiazepine and three antipsychotic 
prescriptions per quarter for a total of six psychoactive prescriptions per quarter for an 
average of five quarters.  Of the total number of seniors in the community, 1,037 (2.1%) 
were chronic users of both benzodiazepines and antipsychotics.   
In long-term care 495 out of 2,843 seniors (17.4%) received two or more 
benzodiazepine and antipsychotic prescriptions per quarter.  Of the 495 seniors, males 
made up 169 (34.1%) of the population and the median age was 82 years.  Over the series 
of twelve quarters between 13.8% and 20.2% of seniors received prescriptions for two or 
more of each psychoactive drug class per quarter (Figure 2.4).  These seniors received an 
average of four benzodiazepine prescriptions and four antipsychotic prescriptions per 
quarter for a total of eight psychoactive prescriptions per quarter for an average of four 
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quarters.  Of the total number of seniors in long-term care, 329 seniors (11.6%) were 
chronic users of both benzodiazepines and antipsychotics.    
 
 
2.4 DISCUSSION  
2.4.1 Summary 
The use of benzodiazepines and antipsychotics remained stable between 2011 and 
2014 in the community and long term care settings in Newfoundland and Labrador 
seniors who were beneficiaries under the provincial drug plan. The use of 
benzodiazepines in the community setting was lower than in long-term care; however, 
over one in five seniors in the community and one in three seniors in long-term care 
facilities used a benzodiazepine in NL.  A pattern of prescribing a single preferred agent 
for both benzodiazepines (lorazepam) and antipsychotics (quetiapine) appears prevalent 
in both the community and long-term care.    
 
2.4.2 Time Trends in Benzodiazepine Utilization   
The proportion of benzodiazepine use in the community was similar to data 
gathered from other provinces studying seniors on public drug plans (CIHI, 2012).  The 
volume of benzodiazepines as described by DDDs in the Newfoundland community was 
similar (132 versus 130) to that found in a similar study done in Nova Scotia (Smith et al., 
2008).  Despite the high rates of use in long-term care facilities as seen in this study, there 
are fewer studies examining benzodiazepine use in the long-term care setting than in the 
community.  In addition, given the differences in populations studied, direct comparisons 
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cannot be made between this study and others.  From the data available, however, 
Newfoundland and Labrador facilities seem to have a higher prevalence than other 
provinces, a difference that may not be entirely due to a skewed population (Bronskill et 
al., 2013; Hagen et al., 2005).   
Of some note is the trend of prescribing one particular benzodiazepine agent 
(lorazepam) to a majority of seniors.  This may be explained by one or more factors: 1) 
lorazepam has fewer drug interactions vs other benzodiazepines, 2) lorazepam has no 
active metabolites, and 3) lorazepam is metabolized via conjugation, which unlike 
oxidation is not impaired by deficiencies in liver function (Powlovich, 2015).  This can be 
considered somewhat reassuring since lorazepam is relatively safe in comparison to other 
benzodiazepines, however the overall prevalence of its prescription should cause concern 
for both clinicians and policy makers.    
 
2.4.3 Time Trends in Antipsychotic Utilization   
Overall use of antipsychotics in Newfoundland and Labrador long-term care 
facilities was higher than the rates reported from the national data (45% versus 39%) 
(CIHI, 2016).  In the long-term care setting, the slight dip in proportion of seniors 
receiving psychoactive drugs (Figure 2.3) can be attributed to the fact that between 
January and April of 2012, the number of seniors in long-term care in Newfoundland and 
Labrador increased by twenty percent from 1,086 to 1,307 residents.  There is a gap in the 
literature discussing the utilization and prevalence of antipsychotics in the community.  
This may be due to the less frequent prescription of antipsychotic medications to seniors 
in the community, especially relative to the long-term care setting.  The average number 
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of DDDs per person per day for antipsychotics in the community may seem low relative 
to the number of prescriptions and relative for the same score for benzodiazepines.  Since 
DDD score is based on the assumption that the drug is being prescribed for its main 
indication, the very low score indicates considerable off label use.   
 
2.4.4 Limitations of the Study  
A brief survey of the limitations of this study should be made in order to properly 
understand the results that it produced.  This study was conducted using only data from 
seniors serviced by the NLPDP, who by definition are of lower income, which has been 
repeatedly associated with poorer health outcomes (Raphael, 2002).  These seniors form a 
specific demographic and the exclusion of higher income seniors from the study means 
that the results may be skewed in relation to the total senior population in this province.   
Additionally, as one finds with nearly all large datasets, there were seniors who had to be 
removed from the study because either their relevant data was missing or could not be 
used.  A total of 1,028 seniors were excluded from the study in comparison to the 52,718 
seniors included in the study.  It is therefore unlikely that those excluded from the study 
had any real effect as the demographic characteristics of those affected by the exclusions 
were similar to those included.  The number of those excluded was relatively small 
compared to the overall number of subjects.   
As this was a secondary study of data collected for another purpose, some 
information was missing that could have been useful to the current research question.  For 
example, reason for the prescription (i.e. diagnosis) would be helpful in order to better 
analyze any differences in specific prescriptions as well as track the most commonly 
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diagnosed condition.  The lack of this information means that there is no way to 
accurately assess the appropriateness of prescriptions written for seniors.  Since only the 
number of medications prescribed is available in this dataset and not the number of 
medications actually taken, drug compliance cannot be accurately measured.  The lack of 
information on physicians means results in the inability to verify whether or not a senior 
had multiple physicians, nor can any patterns be identified within groups of seniors being 
treated by the same physician.   
 
2.4.5 Conclusion 
This study was designed to measure utilization of benzodiazepines and 
antipsychotics in Newfoundland and Labrador.  It was found that the prevalence and rate 
of prescriptions for both benzodiazepines and antipsychotics remained stable over the 
duration of the study.   Studies from other parts of Canada showed that the prevalence of 
benzodiazepine and antipsychotics prescriptions for seniors on public drug coverage was 
found to be higher in Newfoundland and Labrador than other regions (Alessi-Severini et 
al., 2014; Smith et al., 2008, Sivanthan et al., 2015; CIHI, 2017).  This is not an ideal 
comparison however, as the Newfoundland and Labrador data is skewed towards a 
particular demographic.  Further study is required to fully understand the context of 
potentially inappropriate use of benzodiazepines and antipsychotics among all seniors in 
the province and to implement policies to incentivize optimal prescribing of these agents.   
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Table 2.1: Demographic and Clinical Characteristics for the Community Setting 
 
 
 
 
 
 
 
 
 
 
Table 2.2: Demographic and Clinical Characteristics for the Long-Term Care Setting 
 
Quarters Age (mean, SD) % male (mean) CDS (median, IQR) 
    
1-4 84.25, +/-8.09 30.1 6.00, (4.00-7.00) 
    
5-8 84.49, +/-8.05 31.5 5.00, (4.00-7.00) 
    
9-12 84.03, +/-8.69 32.4 5.00, (4.00-7.00) 
    
P-value 0.035 0.007 <0.001 
 
  
Quarters Age (mean, SD) % male (mean) CDS (median, IQR) 
    
1-4 74.36, +/-7.45 43.1 4.00, 3.00-6.00 
    
5-8 73.40, +/-7.45 43.1 4.00, 3.00-6.00 
    
9-12 72.54, +/-7.42 43.1 4.00, 2.00-5.00 
    
P-value <0.001 <0.001 <0.001 
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Table 2.3:  Prevalence, Rate, and Volume of Psychoactive Prescriptions in the 
Community 
 
 
(* indicates five or fewer subjects which cannot be reported for privacy reasons) 
Drug Class/ 
Sub Class 
Agent Number 
People 
With 1+ Rxs 
per Quarter 
(%) 
Number 
People 
With 2+ Rxs 
per Quarter 
(%) 
Number of 
Rxs 
Filled 
 
Total 
DDD 
Total  49,875 49,875 4,579,704  
      
Benzodiazepines  15,455 (31.0) 10,665 (21.4) 221, 405 5,521,747 
Intermediate/Long 
Acting 
     
 Lorazepam 9,290 (60.1) 5,932 (55.6) 86,441 1,870,196 
 Temazepam 2,604 (16.8) 2,153 (20.2) 35,667 1,425,386 
 Clonazepam 2,549 (16.5) 2,079 (19.5) 32,660 1,529,930 
 Diazepam 1,051 (6.8) 728 (6.8) 11,615 416,350 
 Bromazepam 881 (5.7) 737 (6.9) 14,247 328,799 
 Chlordiazepoxide 242 (1.6) 202 (1.9) 3,715 108,484 
 Nitrazepam 209 (1.4) 165 (1.5) 2,753 159,554 
 Potassium 
Clorazepate 
159 (1.0) 141 (1.3) 1,626 42,179 
 Flurazepam 74 (0.5) 58 (0.5) 808 22,704 
 Clobazam 61 (0.4) 57 (0.5) 1,067 31,326 
Short Acting      
 Oxazepam 1,332 (8.6) 1,047 (9.8) 15,622 253,373 
 Alprazolam 828 (5.4) 689 (6.5) 13,425  403,986 
 Triazolam 167 (1.1) 129 (1.2) 1,759 63,679 
      
Antipsychotics  3,066 (6.1) 2,321 (4.7) 546,131 519,824 
Atypical      
 Quetiapine 1,769 (57.7) 1,455 (62.7) 30,733 206,006 
 Risperidone 692 (22.6) 611 (26.3) 11,769 86,002 
 Olanzapine 160 (5.2) 160 (6.9) 5,315 158,738 
 Clozapine * * 142 2,894 
 Aripiprazole * * 75 1,117 
 Ziprasidone * * 71 2,456 
Typical      
 Haloperidol 188 (6.1) 135 (5.8) 1,768 26,915 
 Prochlorperazine 363 (11.8) 100 (4.3) 864 3,230 
 Levomepromazine 110 (3.6) 100 (4.3) 1,804 4,230 
 Perphenazine 53 (1.7) 49 (2.1) 1,385 9,303 
 Chlorpromazine 74 (2.4) 42 (1.8) 961 9,993 
 Trifluoperazine 35 (1.1) 35 (1.5) 1,069 11,364 
 Flupentixol 27 (0.9) 25 (1.1) 562 3,408 
 Zuclopenthixol 9 (0.3) 8 (0.3) 302 3886 
 Periciazine * * 9 101 
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Table 2.4: Prevalence, Rate, and Volume of Psychoactive Prescriptions in Long-Term 
Care    
 
 
(* indicates five or fewer subjects which cannot be reported for privacy reasons) 
 
Drug Class/ 
Sub Class 
Agent Number People 
With 1+ Rxs 
per Quarter 
(%) 
Number People 
With 2+ Rxs 
per Quarter 
(%)   
Number 
of Rxs 
 
Total 
DDD 
Total  2,843  2,843 388,240   
      
Benzodiazepines  1,486 (52.2) 1,046 (36.8) 17,301  715,453 
Intermediate/Long 
Acting 
     
 Lorazepam 1,136 (76.4) 760 (72.7) 8,523 161,775 
 Temazepam 226 (15.2) 207 (19.8) 2,959 125,987 
 Clonazepam 192 (12.9) 178 (17.0) 2,384 12,468 
 Diazepam 75 (5.0) 58 (5.5) 597 26,622 
 Bromazepam 35 (2.4) 34 (3.3) 511 16,471 
 Nitrazepam 10 (0.7) 10 (1.0) 144 9,069 
 Chlordiazepoxide 9 (0.6) 7 (0.7) 87 5,247 
 Potassium Clorazepate * * 67 3,292 
 Clobazam 6 (0.4) * 48 3,169 
 Flurazepam * * * * 
Short Acting      
 Oxazepam 135 (9.1) 121 (11.6) 1,718 25,217 
 Alprazolam 19 (1.3) 17 (1.6) 251 9,654 
 Triazolam 7 (0.5) * 10 906 
      
Antipsychotics  1,273 (44.8) 1,134 (39.9) 21,495 151,541 
Atypical      
 Quetiapine 866 (68.0) 797 (70.3) 14,098 90,563 
 Risperidone 372 (29.2) 342 (30.2) 5,514 37,503 
 Olanzapine 27 (2.1) 27 (2.4) 578 23,291 
 Clozapine * * 14 549 
 Aripiprazole * * 6 245 
Typical      
 Haloperidol 113 (8.9) 86 (7.6) 615 6,038 
 Levomepromazine 16 (1.3) 16 (1.4) 161 632 
 Chlorpromazine 15 (1.2) 13 (1.1) 147 3,681 
 Prochlorperazine 22 (1.7) 12 (1.1) 82 439 
 Flupentixol * * 61 719 
 Perphenazine * * 49 274 
 Trifluoperazine * * 25 1,260 
 Zuclopenthixol * * 9 332 
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Figure 2.1:  Prevalence of Seniors in the Community Receiving Two or More 
Psychoactive Prescriptions   
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Figure 2.2:  Rate of Psychoactive Prescriptions Filled in the Community per 1,000 Total 
Prescriptions  
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Figure 2.3:  Volume of Psychoactive Prescriptions Filled in the Community in 
DDDs/1,000 People/Day 
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Figure 2.4:  Prevalence of Seniors in Long-Term Care Receiving Two or More 
Psychoactive Prescriptions   
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Figure 2.5: Rate of Psychoactive Prescriptions Filled in Long-Term Care per 1,000 Total 
Prescriptions  
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Figure 2.6: Volume of Psychoactive Prescriptions Filled in Long-Term Care in 
DDDs/1,000 people/Day 
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Chapter 3 
Geographic Variation in the Utilization of Benzodiazepines and 
Antipsychotics Across Long-Term Care Facilities and the Community 
Dwelling Seniors in Newfoundland and Labrador 
  
3.1 INTRODUCTION 
3.1.1 Background  
 The high rates of potentially inappropriate benzodiazepine and antipsychotic 
prescriptions among seniors have been well documented in Canada and in other parts of 
the world (Smith et al., 2008; Martinsson et al., 2012).  However, this problem is not 
uniform across geographical regions.  Studies conducted in Canada and the United States 
have shown substantive variation in prescribing practices for benzodiazepines and 
antipsychotics across geographic areas including differences between urban and rural 
settings and among long-term care facilities (Stevenson et al., 2010).   
Studies describing benzodiazepine utilization among community dwelling seniors 
in the US have shown that benzodiazepines (particularly anxiolytics) are prescribed 
approximately 1.5 to 2.5 times more often in rural areas than in urban areas (Edelstein et 
al, 2014), although not all evidence is consistent.  A Canadian study found no difference 
in the use of benzodiazepines in among rural and urban areas (both equal 10.9%) (Alessi-
Severini et al., 2013).   
Similar studies have been done concerning antipsychotics in Canada.  Alessi-
Severini and colleagues have shown that among community dwellers, antipsychotics were 
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more commonly prescribed to urban seniors than rural seniors (p<0.05, OR = 0.88) 
(Alessi-Severini et al., 2013).  In Ontario, a study of residents in long-term care found 
that there was some variation between the different regions of the province in terms of 
antipsychotic prescriptions, ranging from 25.4% to 32.4% (Health Quality Ontario, 2015).  
Similarly, a study conducted across multiple states in the US found that antipsychotic 
prescription in long-term care facilities were significantly influenced by region and 
increased significantly as size of the facility increased (Chen et al., 2010).  
 
3.1.2 Purpose of Study and Objectives 
To further understand variations in benzodiazepine and antipsychotic utilization 
across geographic regions in Newfoundland and Labrador, data was collected from two 
different cohorts of seniors: 1) community dwelling seniors and 2) seniors living in long-
term care facilities.   
  
 
3.2 METHODS 
3.2.1 Population and Inclusion/Exclusion Criteria 
The population for this study was composed of senior citizens 65 years and older 
who, between April 1
st
, 2011 and March 31
st
, 2014, received publically funded drug 
coverage under the provincial prescription drug program (NLPDP) while living in 
Newfoundland and Labrador.  Seniors were recorded as residing in either communities or 
in long-term care facilities.  Seniors were excluded if their demographic information (e.g. 
age, sex) or postal code was missing.  In the long-term care setting, only provincially 
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funded facilities were included in the database, excluding private nursing homes.  
Residents in long-term care facilities were excluded from the study if they spent longer 
than 7 days outside facilities while being transferred from facility to facility.  For long-
term care residents, those who spent more than 7 days outside a facility while being 
transferred were removed from analysis.  To avoid double counting, individuals moving 
from the community into long-term care during the course of the study were analyzed 
only as long-term care residents.  As an exploratory analysis, the variability among 
individual long-term care facilities was also analyzed.   For this analysis, long-term care 
facilities where fewer than thirty residents received the drug of interest (either 
benzodiazepines or antipsychotics) were excluded as the number of subjects would be too 
small to be statistically valid.  This project has been approved by the Health Research 
Ethics Board (HREB #2016.324). 
 
3.2.2 Data Sources    
The study population was derived from three provincially maintained databases: 
1) The NL Prescription Drug Plan (NLPDP) database, which contains 
prescription records for individuals who receive the Guaranteed Income 
Supplement (GIS) and Old Age Security (OAS) benefits (Department of 
Health and Community Services, 2017).  Information collected by the NLPDP 
database includes drug dispensed, date of dispensation, drug dosage, quantity 
dispensed, and days’ supply. 
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2) The Provincial Client Registry, which contains personal demographic 
information such as Medical Care Plan (MCP) number, sex, month and year of 
birth, and postal code. 
3) The Long-Term Care (LTC) Module of the Provincial Meditech database, 
containing information on seniors living in long-term care facilities as well as 
their dates of admission and discharge.  
All data linkages were performed at the Newfoundland and Labrador Centre for Health 
Information (NLCHI) and information was de-identified before being released.   
 
3.2.3 Definitions of Geographic Regions 
3.2.3.1 Geographic Regions in the Community 
Seniors living in the community were categorized as living in either urban or rural 
areas based on Canada Post area codes.  The second character of the postal code identifies 
whether the address is rural or urban.  Canada Post postal codes reflect Statistics Canada 
definitions which delineate urban versus rural communities. An urban area is defined as 
consisting of greater than 1,000 people with a population density of greater than 400 per 
square kilometer (Statistics Canada, 2011).   
 
3.2.3.2 Geographic Regions in Long-Term Care 
Seniors living in long-term care facilities were categorized by their location in one 
of the four regional health authorities (RHA) in the province: Eastern Health, Central 
Health, Western Health, or Labrador-Grenfell Health.  Each long-term care facility in the 
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four RHAs of the province was randomly assigned a number from 1 to 37 to maintain 
anonymity.  
 
 
3.2.4 Measuring Drug Utilization 
For the purposes of this study, any senior who received at least one prescription 
for benzodiazepines or antipsychotics was defined as a user.  The database used detailed 
the specific drug each senior received as well as the strength of each dose.  Each drug is 
identified by its Anatomical Therapeutic Chemical (ATC) code (See Appendices 4.1  
and 4.2).  Drug utilization for both benzodiazepine and antipsychotic prescriptions was 
measured using three different metrics:   
1) Prevalence was calculated as the ratio of the total number of users per quarter 
for benzodiazepines and antipsychotics over the total number of NLPDP 
beneficiaries per quarter.   
2) Rate of prescription was calculated as the ratio of the number of 
benzodiazepine or antipsychotic prescriptions records per 1,000 over the total 
number of prescriptions per quarter.  Calculation included only prescriptions 
claims confirmed as paid.   
3) Volume, as the total number of defined daily doses (DDDs) per quarter per 
drug, was calculated.  The World Health Organization (WHO) defines DDD 
as the “assumed average dose per day of a drug in adults, as prescribed for its 
main indication” (WHO Collaborating Centre for Drug Statistics 
Methodology, 2009).  Total DDD is calculated by obtaining the product of the 
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strength of the dose and the number of days’ supply then dividing by one 
DDD.  Total DDD is generally reported in the literature as DDDs per 1,000 
people per day with takes into account the number of days in the prescription.     
 
3.2.5 Statistical Analysis 
All analyses for seniors living in the community and seniors in long-term care 
facilities were conducted separately from each other.  The data analyzed covered a three 
year period from April 2011 to March 2014.  Descriptive statistics were used to 
summarize the study population.  The significant differences between groups for 
continuous variables were examined by t-test and discrete variables were tested using chi-
squared tests.  To adjust other confounders, multivariate regression models were used.   
Specifically, logistic regression models were used to test regional differences in 
the prevalence of people taking either benzodiazepines or antipsychotics (dichotomous 
variable).  Poisson regression models were used to analyze differences in the rate of 
prescriptions use between regions (count variable). Linear regression modelling was used 
to measure differences in volume across geographic locales (proportion variable).  
Volume was measured as the defined daily dose per 1,000 people per day.  The primary 
variable for the modelling was area in the community setting and facility in the long-term 
care setting.  Individual facilities where at least thirty residents received either 
benzodiazepine or antipsychotic prescriptions were analyzed for prevalence, rate, and 
volume.   
For the multivariate analyses age, sex, and chronic disease score were used as 
covariates in the models.  Age was measured as a continuous variable and sex as a binary 
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variable (male=0, female=1), as it was recorded in the dataset.  The chronic disease score 
(CDS) is a prescription based comorbidity score where one point is given to an individual 
corresponding to each drug class they are prescribed with a maximum score of 24 points.  
An increased chronic disease score is associated with an increased risk of one year all-
cause hospitalization and mortality (Lix et al., 2016).  Potential interactions between 
facility size and prevalence were also analysed. 
   The models were constructed using backwards elimination with nonsignificant 
variables being removed one at a time.  Testing was completed on all models as well as 
all two-way interactions for the models.  No violations of the usual assumptions such as 
linearity and homoscedasticity were found.   All statistical analyses were conducted using 
SPSS, version 23. 
 
 
3.3 RESULTS 
3.3.1 Overview of the Community  
 Out of the original 53,746 seniors in the database overall, 1,028 seniors were 
excluded from the analysis, most of which were community dwelling.  After the 
exclusion, there were 49,875 seniors in the community, of whom 18,480 (37.1%) lived in 
urban areas and 31,395 (62.9%) lived in rural areas.  Of the 4,579,704 prescriptions filled 
in the community, 1,748,256 (38.2%) of them were filled in urban areas and 2,830,448 
(61.8%) of them were filled in rural areas.  In urban areas the median age was 74 years, 
38.7% of seniors were male, the median CDS was four, and the average senior received 
ten prescriptions per quarter for an average of nine quarters.  In rural areas the median age 
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was 73 years, 43.9% of them were male, median CDS was four, and the average senior 
received ten prescriptions per quarter for an average of nine quarters (Table 3.1).   
 
3.3.2 Overview of Long-Term Care Facilities 
 Of the 2,843 seniors in long-term care facilities 1,983 (69.8%) were in Eastern 
Health, 659 (23.2%) were in Central Health 153 (5.4%) were in Western Health, and 48 
(1.7%) were in Labrador-Grenfell Health.  There was a total of 388,240 prescriptions 
filled, of which 310,914 (80.1%) were filled in the Eastern Health, 59,502 (15.3%) were 
filled in the Central Health, 11,237 (2.9%) were filled in Western Health, and 6,587 
(1.7%) were filled in Labrador-Grenfell Health.   
In Eastern Health the median age for seniors in long-term care was 84 years, 
30.8% were male, the median CDS was five, and the average senior received 26 
prescriptions per quarter for an average of six quarters.  In Central Health the median age 
for seniors in long-term care was 84 years, 31.0% were male, the median CDS was five, 
and the average senior received twenty prescriptions per quarter for an average of four 
quarters.  In Western Health the median age for seniors in long-term care was 82 years, 
34.6% were male, the average CDS was five, and the average senior received 23 
prescriptions per quarter for an average of three quarters.  In Labrador-Grenfell Health the 
median age for seniors in long-term care was 85 years, 22.9% were male, the average 
CDS was 4.5 and the average senior received nineteen prescriptions per quarter for an 
average of seven quarters (Table 3.2). 
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3.3.3 Benzodiazepine Prescription in the Community  
 Of the 18,480 seniors living in urban areas, 5,632 (30.5%) received at least one 
prescription for benzodiazepines during the three year period.  Of the 31,395 seniors 
living in rural areas 8,227 (26.2%) received at least one prescription for benzodiazepines 
within the three year period (Table 3.3).  When age, sex, and CDS were controlled for, 
prevalence was significantly higher for seniors in urban areas versus rural areas (p<0.001; 
OR=1.273; 95%CI=1.217,1.332).  The average rate of benzodiazepine prescriptions per 
1,000 total prescriptions was 55 in urban areas and 44 in rural areas.  After controlling for 
age, sex and CDS the difference in rate of prescription between areas was significantly 
higher in urban areas (p<0.001; OR=1.139; 95%CI=1.101,1.178).  The average volume 
measured by DDDs per 1,000 people per day was 166 in urban areas and 116 in rural 
areas.  After controlling for age, sex and CDS the difference in volume between areas was 
significant with volume in urban areas being higher (p<0.001; DDD difference=63.1; 
95%CI=48.2,78.1). 
 
3.3.4 Antipsychotic Prescription in the Community  
 Of the 18,480 seniors living in urban areas, 1,308 (7.1%) received at least one 
prescription for antipsychotics within the three year period.  Of the 31,395 seniors living 
in rural areas, 1,758 (5.6%) received at least one prescription for antipsychotics within the 
three year period (Table 3.3).  However when age, sex, and CDS were controlled for, 
prevalence was significantly higher for seniors in urban areas versus rural areas (p<0.001; 
OR=1.266 ; 95%CI=1.172,1.368).  The average rate of antipsychotic prescription per 
1,000 total prescriptions per was fifteen in urban areas and ten in rural areas. After 
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controlling for age, sex and CDS the difference in rate of prescription between areas was 
significant with urban areas having a higher rate (p<0.001; OR=1.105; 95%CI=1.022, 
1.194).  The average volume, measured as DDDs per 1,000 people per day, was nineteen 
in urban areas and ten in rural areas.  After controlling for age, sex and CDS the 
difference in volume between areas was significant with urban areas having a higher 
volume (p=0.005; DDD Difference=7.3; 95%CI=-2.8,17.3). 
 
3.3.5 Benzodiazepine Prescription in Long-Term Care 
 The prevalence of benzodiazepine prescriptions in long-term care was 56.2% 
(N=1,114 people) in Eastern Health, 54.8% (N=361 people) in Central Health, 56.2% 
(N=86 people) in Western Health, and 29.2% (N=14) in Labrador-Grenfell Health (Table 
3.4).  After controlling for age, sex, and CDS the overall difference in the prevalence of 
benzodiazepine prescriptions is significant (Wald Chi-Square p=0.005).  When 
comparing pairwise differences however, Labrador-Grenfell Health facilities were the 
only facilities that had  significantly lower prevalences than Eastern Health facilities 
(p<0.001; OR=0.857; 95%CI=0.398,1.405).   
The average rate of benzodiazepine prescriptions in long-term care was 47 per 
1,000 total prescriptions in Eastern Health, 50 per 1,000 in Central Health, 50 per 1,000 in 
Western Health, and twenty per 1,000 in Labrador-Grenfell Health.  After controlling for 
age, sex, and CDS there was no significant difference overall in the rate of 
benzodiazepine prescription between the four RHAs (Wald Chi-Square p=0.590).  The 
volume of benzodiazepine prescriptions in long-term care (as measured in DDDs per 
1,000 people per day) was 191 in Eastern Health, 122 in Central Health, 158 in Western 
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Health, and 105 in Labrador-Grenfell Health.  After controlling for age, sex, and CDS 
there was no significant difference in volume of benzodiazepines prescribed between the 
four RHAs (Wald Chi-Square p=0.110). 
  After controlling for age, sex, and CDS, the difference in prevalence between 
facilities for benzodiazepine prescription was significant (Wald Chi-Square p<0.001), 
with results ranging from 36% to 73% (Figure 3.1).  There was no interaction between 
age, sex, or CDS and facility size.  Rate of benzodiazepine prescriptions was also 
significant (Wald Chi-Square p=0.038), with results from 30 to 80 benzodiazepine 
prescriptions per 1,000 total prescriptions (Figure 3.2).  The volume of benzodiazepine 
prescriptions was not statistically significant (Wald Chi-Square p=0.130) after controlling 
for age, sex, and (Figure 3.3).   
 
3.3.6 Antipsychotic Prescription in Long-Term Care 
 The prevalence of antipsychotic prescriptions in long-term care was 48.0% 
(N=952 people) in Eastern Health, 43.2% (N=285 people) in Central Health, 45.1% 
(n=69 people) in Western Health, and 35.4% (N=17 people) in Labrador-Grenfell Health 
(Table 3.2).  After controlling for age, sex, and CDS there was no significant difference in 
the prevalence of antipsychotic prescription between the four RHAs (p=0.120).  The rate 
of antipsychotic prescriptions in long-term care was 58 per 1,000 total prescriptions in 
Eastern Health, 47 per 1,000 in Central Health, 50 per 1,000 in Western Health, and 50 
per 1,000 in Labrador-Grenfell Health.  After controlling for age, sex, and CDS there was 
no significant difference in the rate of antipsychotic prescriptions between the RHAs 
(p=0.125).  The volume of antipsychotic prescriptions in long-term care (as measured in 
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DDDs/1,000 people/day) was 95 in Eastern Health, 65 in Central Health, 62 in Western 
Health, and 52 in Labrador-Grenfell Health.  After controlling for age, sex, and CDS 
there was no significant difference in volume of antipsychotics prescribed between the 
RHAs (p=0.088).  
 After controlling for age, sex, and CDS, the difference in prevalence between 
facilities for antipsychotic prescription was significant (p<0.001) with results ranging 
from 35% to 78% (Figure 3.4).  There was no interaction between age, sex, or CDS and 
facility size.  After controlling for age, sex, and CDS, neither rate or volume of 
antipsychotic prescriptions was statistically significant across the facilities (p=0.248 and 
p=0.087 respectively) (Figures 3.5 & 3.6).   
 
 
3.4 DISCUSSION  
3.4.1 Summary 
 In the community setting the prevalence, rate, and volume of prescriptions was 
significantly higher in urban areas for both benzodiazepines and antipsychotics.   In the 
long-term care setting the prevalence of benzodiazepine prescriptions was significantly 
different across the four RHAs (p>0.005).  However, when analysed in a pairwise 
fashion, only Labrador-Grenfell Health had a prevalence significantly different (and 
lower) from Eastern Health.  
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3.4.2 Geographic Distribution in the Community  
Benzodiazepines in the community setting were more likely to be prescribed to 
urban residents in terms of prevalence, rate, and volume.  The results from this study 
differ from others comparing urban versus rural benzodiazepine prescription (Alessi-
Severini et al., 2013; Edelstein et al., 2014).  Most studies conducted in North America 
found no significant difference between prescription patterns of benzodiazepines in urban 
versus rural settings, or found higher levels in rural settings.   
Female sex and advanced age in seniors have both been linked to have been linked 
to prescription of benzodiazepines and antipsychotics (Bartlett et al., 2009; Sivanthan et 
al., 2015).   These variables, however, were controlled for by the regression used for this 
analysis.  With that being said, other variables may play a role in the dissimilarity in 
prevalence, rate, and volume of benzodiazepine prescriptions between in urban and rural 
dwelling seniors in the province.  For benzodiazepines, prescriptions have been 
associated with diagnoses of chronic pain, depression, and low alcohol consumption 
(Bartlett et al. 2009; Dias dos Anjos Cunha et al., 2015).  For antipsychotics, prescriptions 
have been associated with a diagnosis of depression and relatively lower income 
(Stevenson et. al, 2010; Sivanthan et al., 2015).    
 
3.4.3 Geographic Distribution in Long-term Care    
 In long-term care, RHA significantly influenced the prevalence of 
benzodiazepines with Labrador-Grenfell residents significantly less likely to receive a 
prescription.  Rate and volume of benzodiazepine prescription remained relatively stable.  
The prevalence, rate, and volume of antipsychotic prescriptions remained stable for all 
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regional health authorities.  One of the factors that may contribute to the difference in 
prevalence of psychoactive prescriptions is size of the facility.  As shown in the study by 
Chen et al. (2010) the size of a facility is significantly and positively correlated to 
prescription prevalence of psychoactive drugs.  Eastern Health facilities house 70% of 
facility dwelling seniors and also have nine of the ten largest facilities in the province.   
The other more intangible factor is the idea of the culture of the regional authority 
and the facilities within them.  For this reason it may also be useful to examine facilities 
individually.  While each regional health authority has a different administration, each 
long-term care facility with the authority is run by individuals who each have their own 
unique approach to patient care.  Hughes et al. (2007) wrote that the individual culture of 
a facility greatly influences how things are done including which residents do or do not 
receive prescriptions for potentially harmful medications.  Various agencies in Canada 
have created list of ways to change the culture of a facility to better implement healthy 
prescribing practices.  These include getting consent from resident/family, agreeing on 
appropriateness criteria, establish regular reviews, and pursuing non-pharmacologic 
interventions (Alberta Health Services, 2016; Bueckert et al., 2016).   
 
3.4.4 Limitations of the Study  
A brief overview of the limitations of this study should be examined to properly 
understand the results that it produced.  This study was conducted using only data from 
seniors serviced by the NLPDP.  Seniors not receiving NLPDP were excluded from the 
study.  This means that the results are not be generalizable to all seniors in Newfoundland 
and Labrador, particularly those whose income is high enough not to be eligible for 
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provincial drug coverage.  The relatively smaller sizes of the samples for the Western and 
Labrador-Grenfell regions also made it that some of the results of the regression analysis 
were less firmly robust than in the Eastern and Central regions.  This would have affected 
the power of the overall statistical power.  Finally, as one finds with almost the entirety of 
large datasets, there were seniors who had to be removed from the study because either 
their relevant data was missing or could not be used.  Those excluded totalled 1,028 
seniors, in comparison to the 52,718 seniors included in the study.  It is unlikely that 
those excluded from the study had any real effect as the number of those excluded in 
relatively small and their demographic characteristics were similar to those included in 
the study.  
As his is first research of its kind to be done in province, further research is 
necessary to fully understand the utilization of psychoactive medication in Newfoundland 
and Labrador.  As this was a secondary study of administrative data, some information 
was missing that could have been useful to the current research question.  It was 
impossible to tell an initial prescription from a refill or ordered prescriptions versus a 
prescription being filled as required.  Since this dataset only shows the number of 
medications prescribed and not the number of medications actually taken, drug 
compliance cannot be accurately measured though it could be different depending on 
geographic area.  The lack of information about prescribing physicians results in the 
inability to verify whether or not a senior had multiple physicians.  It is also impossible to 
determine whether or not the physician was a specialist, or whether any patterns be 
identified within groups of seniors being treated by the same physician.  In terms of 
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regional health authority for the long-term care setting, further research should examine 
the interaction between level of care and the prevalence of psychoactive prescription.      
 
3.4.5 Conclusion 
This study was designed to measure the geographic variation of benzodiazepines 
and antipsychotics in Newfoundland and Labrador.  It was found that the prevalence and 
rate of prescriptions for both benzodiazepines and antipsychotics was significantly 
influenced by geography in both the community and long-term care settings.   Other 
studies from different parts of North America reached similar conclusions but the 
distribution patterns in this province appears higher to those regions previously studied, 
possibly being explained by the demography of the study subjects.  Further study is 
required that includes all seniors in the province and specifically includes diagnosis and 
severity in order to gain a better understanding of what is and what is not inappropriate 
prescribing amongst our seniors.  After this has been established health care providers and 
policy makers must collaborate to draw up viable ways to optimize prescription practices.   
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Table 3.1: Demographic and Clinical Characteristics for the Community Setting 
 
Area Sample Size Age (mean, SD) % male (mean) CDS (median, IQR) 
     
Urban 18,488 76.94, +/- 8.02 38.7 4.00, 2.00-5.00 
     
Rural 31,395 75.66, +/- 7.55 45.4 4.00, 2.00-5.00 
     
P-Value  p<0.001 p<0.001 p=0.961 
 
 
 
 
Table 3.2: Demographic and Clinical Characteristics for the Long-Term Care Setting 
 
LTC Facility Sample Size Age (mean, SD) % male 
(mean) 
CDS (median, 
IQR) 
     
Eastern  1,983 85.21, +/-8.50 30.8 5.00, 4.00-7.00 
     
Central 659 85.26, +/-7.95 31.0 5.00, 3.00-7.00 
     
Western 153 83.71, +/-7.43 34.6 5.00, 4.00-7.00 
     
Labrador-Grenfell  48 86.23, +/-7.77 22.9 4.50, 3.00-7.00 
     
P-Value  p=0.129 p=0.486 p=0.373 
 
 
 
Abbreviation(s): 
CDS: chronic disease score 
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Table 3.3: Utilization of Benzodiazepines and Antipsychotics in the Community 
 
Drug Class/Utilization Urban Rural 
Benzodiazepine   
Sample Size 5,632 8,227 
   
Prevalence (%) 30.5 26.2 
cOR (95%CI) 1.234 (1.186,1.285) ref 
aOR (95%CI) 1.273 (1.217,1.332) ref 
   
Rate (Rxs/1,000 Total) 55 44 
cRR (95%CI) 1.156 (1.115,1.198) ref 
aRR (95%CI) 1.139 (1.101,1.178) ref 
   
Volume (DDD/1,000 People/Day) 166 116 
cDiff (95%CI) 58.8 (44.2,73.3) ref 
aDiff (95%CI) 63.1 (48.2,78.1) ref 
   
Antipsychotic   
Sample Size 1,308 1,758 
   
Prevalence (%) 7.1 5.6 
cOR (95%CI) 1.284 (1.193,1.383) ref 
aOR (95%CI) 1.266 (1.172,1.368) ref 
   
Rate (Rxs/1,000 Total) 15 10 
cRR (95%CI) 1.112 (1.021,1.210) ref 
aRR (95%CI) 1.105 (1.022, 1.194) ref 
   
  Volume (DDD/1,000 People/Day) 19 10 
cDiff (95%CI) 8.2 (-2.2,18.7) ref 
aDiff (95%CI) 7.3 (-2.8,17.3) ref 
  
 
Abbreviations: 
cOR: crude odds ratio 
aOR: adjusted odds ratio 
DDD: defined daily dose    
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Table 3.4: Utilization of Benzodiazepines and Antipsychotics in Long-Term Care 
 
Drug Class/Utilization Eastern Central Western L-Grenfell 
Benzodiazepine     
Sample Size 1,114 361 86 14 
     
Prevalence (%) 56.2 54.8 56.2 29.2 
cOR 
 (95%CI) 
ref 0.945 
(0.792,1.128) 
1.001 
(0.719,1.395) 
0.321 
(0.171,0.602) 
aOR  
(95%CI) 
ref 0.984 
(0.812,1.192) 
0.954 
(0.665,1.367) 
0.295 
(0.150,0.578) 
     
Rate (Rxs/1,000 Total) 47 50 50 20 
cRR  
(95%CI) 
ref 1.089 
(0.959,1.237) 
1.050 
(0.827,1.334) 
0.857 
(0.398,1.405) 
aRR  
(95%CI) 
ref 1.083  
(0.964,1.218) 
1.060 
(0.849,1.324) 
1.046 
(0.656,1.668) 
     
Volume (DDD/1,000 
People/Day) 
191 122 158 105 
cDiff 
 (95%CI) 
ref -69.4 
(-129.0,-9.8) 
-34.0 
(-144.7,76.8) 
-86.9 
(-351.5,177.8) 
aDiff  
(95%CI) 
ref -71.9 
(-131.2,-12.5) 
-46.5 
(-156.9,64.0) 
-68.0 
(-331.8,195.8) 
     
Antipsychotic     
Sample Size 952 285 69 17 
     
Prevalence (%) 47.8 43.2 45.1 35.4 
cOR 
 (95%CI) 
ref 0.825 
(0.691,0.986) 
0.890 
(0.639,1.238) 
0.594 
(0.327,1.080) 
aOR  
(95%CI) 
ref 0.837 
(0.697,1.005) 
0.830 
(0.589,1.168) 
0.630 
(0.340,1.167) 
     
Rate (Rxs/1,000 Total) 58 47 50 50 
cRR  
(95%CI) 
ref 0.866 
(0.775,0.968) 
0.779 
(0.598,1.014) 
1.082 
(0.720,1.626) 
aRR  
(95%CI) 
ref 0.897 
(0.814,0.987) 
0.882 
(0.699,1.113) 
0.997 
(0.666,1.495) 
     
  Volume (DDD/1,000 
People/Day) 
95 65 62 52 
cDiff  
(95%CI) 
ref -30.2 
(-55.4,-4.9) 
-33.0 
(-80.1,14.1) 
-43.3 
(-134.5,47.8) 
aDiff  
(95%CI) 
ref -27.5 
(-52.1,-2.9) 
-33.2 
(-79.2,12.8) 
-36.5 
(-125.3,52.3) 
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Figure 3.1:  Prevalence of Seniors in Long-term Care Receiving One or More 
Benzodiazepine Prescriptions by Facility  
 
 
 
EHF = Eastern Health Facility 
CHF = Central Health facility 
WHF = Western Health Facility 
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Figure 3.2:  Rate of Benzodiazepine Prescriptions Filled in Long-Term care per 1,000 
Total Prescriptions by Facility 
 
 
  
 
EHF = Eastern Health Facility 
CHF = Central Health facility 
WHF = Western Health Facility 
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Figure 3.3:  Volume of Benzodiazepine Prescriptions Filled in Long-Term Care by 
Facility Measured as DDDs per 1,000 People per Day  
 
 
EHF = Eastern Health Facility 
CHF = Central Health facility 
WHF = Western Health Facility 
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Figure 3.4:  Prevalence of Seniors in Long-term Care Receiving One or More 
Antipsychotic Prescriptions by Facility   
 
 
 
 
EHF = Eastern Health Facility 
CHF = Central Health facility 
WHF = Western Health Facility 
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Figure 3.5:  Rate of Antipsychotic Prescriptions Filled in Long-Term care per 1,000 Total 
Prescriptions by Facility 
 
 
 
EHF = Eastern Health Facility 
CHF = Central Health facility 
WHF = Western Health Facility 
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Figure 3.6:  Volume of Antipsychotic Prescriptions Filled in Long-Term Care by Facility 
Measured as DDDs per 1,000 People per Day 
 
 
 
EHF = Eastern Health Facility 
CHF = Central Health facility 
WHF = Western Health Facility 
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   Chapter 4 
Discussion and Conclusion 
 
4.1 SUMMARY OF MAJOR ISSUES  
The studies conducted in this thesis have been undertaken to develop a better 
understanding of the patterns of utilization of benzodiazepines and antipsychotics 
amongst seniors in Newfoundland and Labrador.  Interest is this area has, at least in part, 
been prompted by the publishing of several warnings by multiple government agencies in 
Canada about the proliferation of prescription drugs in the country which have been 
associated with serious adverse effects in seniors (Health Canada, 2012; Government of 
Canada, 2014; CIHI, 2014).   
Seniors in Canada comprise 14% of the total population but account for 44% of 
healthcare expenditures due to higher medication use, more frequent visits to family 
doctors, and longer and more frequent stays in hospitals (CIHI, 2010; CMA, 2013).  An 
additional factor that exacerbates the situation in Newfoundland and Labrador is that the 
province, along with the rest of Atlantic Canada, has one of the highest median ages in 
the country (Stats Canada, 2016).  For these reasons, an in-depth examination of 
benzodiazepine and antipsychotic utilization for seniors should provide valuable insight 
to clinicians and policy makers in the province.           
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4.2 SUMMARY OF THE STUDIES 
The rate of benzodiazepine and antipsychotic prescriptions stayed constant during 
the three year study period in both the long term care and community settings for seniors 
who were provincial drug plan beneficiaries in Newfoundland and Labrador.  The 
prevalence of prescriptions for both drug classes in the community was significantly 
higher in urban versus rural areas.  Prevalence of prescriptions in long-term care facilities 
was significantly different across the four RHAs with Labrador-Grenfell Health having 
the lowest for both benzodiazepine and antipsychotic prescriptions.  Single agents for 
both benzodiazepines (lorazepam) and antipsychotics (quetiapine) were shown to 
comprise the majority of prescriptions in both the community and long-term care settings.    
 
 
4.3 DISCUSSION OF STUDY ONE RESULTS 
4.3.1 Time Trends for Benzodiazepine Prescription 
In the community, utilization remained stable over time in terms of prevalence, 
rate, and volume.  An average of 21.4% of seniors received two or more prescriptions for 
benzodiazepines per quarter at a rate of 48 prescriptions per 1,000 total prescriptions.  
The average volume of benzodiazepine prescriptions as indicated by DDDs per 1,000 
people per day in Newfoundland and Labrador was similar if slightly higher (132 versus 
130) than found in a study conducted in Nova Scotia (Smith et al., 2008) and remained 
stable over time.  The similarity can be expected since Nova Scotia has a comparable 
demographic distribution to Newfoundland and Labrador by age and sex (Stats Canada, 
2015).   
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Prevalence and rate for benzodiazepine prescriptions in long-term care facilities 
remained stable over time.  An average of 36.8% of seniors received at least two 
benzodiazepine prescriptions per month at a rate of 45 prescriptions per 1,000 total 
prescriptions.   The volume of benzodiazepine prescriptions as indicated by DDDs per 
1,000 people per day remained stable at an average of 192.   
The higher prevalence and volume of benzodiazepine prescriptions is to be 
expected in long-term care residents given their age and the increasing complexity of 
their medical needs, prompting their entrance into facilities in the first place.  However, 
since seniors have a much higher risk of adverse effects, this practice can be risky for 
their long-term care.  Reference has already been made of the fact that lorazepam is the 
most commonly prescribed benzodiazepine for seniors.  This may be attributed to the fact 
that it produces fewer drug interactions than other benzodiazepines, has no active 
metabolites, and uses a system of metabolization that is appropriate for the elderly 
(Powlovich, 2015).  Another reason that lorazepam may be preferred over other 
benzodiazepines is the relatively shorter half-life of the drug, decreasing buildup in the 
system which in turn decreases the risk of adverse effects (Salzman, 1990).   
The prescription of benzodiazepines for insomnia in seniors is considered 
inappropriate as the drug agents chosen tend to be of the longer-acting variety, meaning 
they stay in the patients’ system for longer, increasing the risk of adverse effects.   As has 
been mentioned in previous chapters, benzodiazepine use (especially long-term use) 
increases the risk of cognitive impairments, falls and fractures, and motor vehicle 
accidents (Smith et al., 2008; Edelstein et al., 2014; Thomas, 1998).  Despite warnings 
from the literature, this study shows that more than one quarter of seniors in the 
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community who were chronic users of benzodiazepines were prescribed intermediate- or 
long-acting benzodiazepines.  In addition, more than one fifth of residents in long-term 
care facilities were prescribed these benzodiazepines on a long-term basis, which is a 
significant predictor of adverse drug events.               
 
4.3.2 Time Trends for Antipsychotic Prescription 
Antipsychotic prescription levels in the community remained stable over time in 
term of prevalence, rate, and volume.  An average of 4.7% of seniors received two or 
more prescriptions for antipsychotics per quarter at a rate of 12 prescriptions per 1,000 
total prescriptions.  The volume of antipsychotic prescriptions as indicated by DDDs per 
1,000 people per day was 13.  As mentioned in previous chapters, there is a gap in the 
literature on the use of antipsychotics in the community.  A likely reason is that they are 
prescribed so infrequently in the community setting due to the rarity of the symptoms 
requiring their use.   The black box warning that exists on their prescription to seniors 
may further discourage their use.  Another reason may be that seniors with symptoms of 
dementia which would be treated by antipsychotics would have difficulty living in a 
community setting as they would require significant care.       
The Canadian Institute for Health Information (CIHI, 2016) reported the national 
prevalence of antipsychotic prescriptions in nursing homes to be 39% in 2014.  In 
comparison, the rate for the three years covered by this study remained stable at an 
average of 44.8% with 39.9% of residents receiving two or more prescriptions per 
quarter.  Rate remained stable over time at 55 prescriptions per 1,000 total prescriptions.  
Volume also remained stable over time at 46 DDDs per 1,000 people per day.  There is 
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some question as to why prevalence of prescription in Newfoundland and Labrador 
exceeds the national average.   The work-place “culture” of the facilities would appear to 
be a good starting point for study.  Hughes et al. (2007) discussed how differences in 
individual facilities due to staff differences affected prescription rates.  As shown in the 
second study, there are differences in the utilization of benzodiazepines and 
antipsychotics across the facilities.  Given the low volume of antipsychotic prescription as 
well as the high prevalence (45%), it can be reasonably assumed that most antipsychotic 
prescriptions being issued in long-term care facilities are not for the treatment of 
psychosis, their main indication (CAMH, 2012).  The introduction of provincial policy on 
psychoactive prescription in long-term care would be a vial step in addressing these 
differences.    
Another approved indication for the prescription of antipsychotics in seniors (for 
risperidone only) is the short-term treatment of severe symptoms of Alzheimer’s disease 
(Health Canada, 2012).  The results of this study indicate, however, that only 29% of 
facility residents receiving antipsychotics received them for one quarter only and only 
11% received on prescription.  The other 71% or residents received at least two 
prescriptions per quarter for a minimum of two quarters.  Since no data is available to 
indicate the diagnosis warranting the prescription of antipsychotics it is uncertain why 
residents received these prescriptions.  Statistics Canada (2016) states that the average 
rate of dementia in long-term care facilities is 45% across the country.  If these numbers 
are accurate for the data in this study, then all residents with dementia in long-term care 
facilities must have been treated for significant psychosis or severe and violent symptoms 
of Alzheimer’s disease at least once during a three year period. A more plausible 
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explanation for these results is that there appears to be an over utilization of antipsychotic 
medications in long-term care facilities in the province, especially since 31% of residents 
were chronic users of antipsychotics, which significantly increase the risk of adverse 
effects.    
 According to studies released by the Canadian Institute for Health Information 
(CIHI, 2012; CIHI, 2016), the total prevalence of antipsychotic prescriptions for seniors 
has decreased in some provinces but increased in others.  British Columbia, Ontario, and 
Manitoba saw decreases in their overall antipsychotics prescribing patterns but provinces 
in the Maritimes reported an increase.  Factors contributing to this phenomenon may 
include the increasing median age of the Atlantic provinces (Statistics Canada, 2011) as 
well as the more developed policies by other provinces in other parts of Canada which 
influence Canada wide policy as a result of more research being conducted in these 
provinces (Bueckert et al., 2017). 
The class of antipsychotic (typical versus atypical) has also changed over time 
throughout the country as the newer atypicals became more widely available.  Use of 
atypical antipsychotics has been increasing over the past few decades since their release 
while the use of typical antipsychotics has been correspondingly decreasing.  It is worth 
noting that while atypical antipsychotics were designed specifically to decrease the 
frequency of EPS, there are studies suggesting that they do not significantly decrease the 
risk of falls and fractures in seniors, a major concern in this vulnerable population (Hien 
Le et al., 2005; Steinberg & Lykos, 2012). 
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4.4 DISCUSSION OF STUDY TWO RESULTS 
4.4.1 Geographic Distribution of Benzodiazepine Use  
Results from this study show that urban dwelling seniors in the community setting 
were more likely to be prescribed benzodiazepines than rural dwelling seniors.  They 
received significantly more benzodiazepine prescriptions and in higher doses (indicated 
by DDDs per 1,000 people per day) than their rural dwelling counterparts.   
Differences in the prevalence, rate, and volume of benzodiazepine prescriptions 
may be due to the difference in lifestyle that exists between urban and rural dwelling 
seniors.  One possible explanation of these results is that urban dwelling seniors may be 
more likely to live alone relative to rural dwelling seniors, resulting in an increased 
feeling of isolation and anxiety requiring treatment with benzodiazepines.  Rhee et al. 
(2011) found that seniors living with caregivers were significantly less likely than those 
living alone to be prescribed antipsychotics, the same could be true for benzodiazepines.   
In the long-term care setting, the prevalence of benzodiazepine prescription 
remained similar among the Eastern, Central, and Western Health regions but was 
significantly (p<0.05) lower for the Labrador-Grenfell Health region.  This may be due to 
the fact that the Labrador-Grenfell Health authority has fewer residents in facilities 
compared to the other authorities.  The small number of people in these facilities would 
also enable more personal care of residents, lowering the need for the prescription of 
psychoactive medications to regulate disruptive behaviour.    
The prevalence of benzodiazepine prescriptions was significantly different for the 
facilities where at least 30 residents received benzodiazepine prescriptions.  Currently, 
prescribers in each facility have their own criteria that determine whether a resident 
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requires a prescription.  Policy changes could institute province-wide regulations that 
would standardize the criteria required to prescribe a medication to a resident, especially 
when the medication in question causes well documented and serious adverse effects.  
Regular mandated review of a patient’s medication use and a systematic application of 
deprescribing guidelines would also help optimize benzodiazepine use in long term care 
facilities.         
 
4.4.2 Geographic Distribution of Antipsychotic Use  
 The prevalence, rate and volume of antipsychotic prescriptions in the community 
were all significantly higher in urban areas relative to rural areas.  An explanation for this 
finding has already been presented in the previous section, where Rhee et al. (2011) found 
that seniors who lived with care givers were significantly less likely to be prescribed 
antipsychotic medication.   
Prevalence, rate, and volume were all highest in the facilities in the Eastern Health 
RHA, with prevalence being significantly lower in the Labrador-Grenfell region facilities 
when compared in a pairwise fashion (p>0.05).  All other outcomes showed no significant 
difference across the four RHAs.  One reason that could contribute to Eastern Health 
consistently having higher results for all three outcomes is facility size.  The Eastern 
Health region has nine of the most populated long-term care facilities in the province, the 
largest of which has 156 residents.  As shown in the study by Chen et al. (2010) the size 
of a facility is significantly and positively correlated to prescription prevalence of 
psychoactive drugs.  Operating style and work culture at facilities can also affect the 
prescription of psychoactive medications.  The American study by Hughes et al. (2007) 
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reports that such “cultures” dictate important aspects of facilities including the 
prescription of medications to its residents.  
 
 
4.5 LIMITATIONS OF THE STUDIES   
Taken together, study one and study two give a fairly comprehensive overview of 
the patterns of utilization for benzodiazepines and antipsychotics amongst seniors in 
Newfoundland and Labrador.   There are limitations, however, that need to be considered 
when interpreting the findings.  The analysis of seniors living in the community setting 
relied upon data from those receiving coverage under the NLPDP.   Therefore, the results 
cover that portion of seniors in Newfoundland and Labrador (approximately 80%) and not 
the total senior population.  Similarly, data from long-term care facilities that are publicly 
funded were included in the analysis, thus excluding those living in private care homes.   
Data used for analysis in these studies were initially collected for administrative 
purposes.  It would have been useful to have access to data that would have expanded and 
enhanced the research questions undertaken in these studies.  For example, reason for the 
prescription (that is the diagnosis) would be helpful to correlate a diagnosis with a 
prescription and monitor the most commonly diagnosed conditions in seniors.  The 
available data tracks the number of medications prescribed but not the number of 
medications taken.  Drug compliance, therefore, cannot accurately be measured.  The lack 
of information on physicians prescribing medications results in the inability to verify 
whether or not a senior received prescriptions from multiple physicians.  Any patterns of 
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prescriptions within groups of seniors being treated by the same physician could not be 
determined with the existing data.   
Additionally, long-term care facilities fill out resident assessment instruments 
(RAIs) annually for each of their residents.  RAIs are a series of assessment tools that 
document what treatments or interventions a resident is receiving and the resident’s 
progress in response to them.  The information from RAIs could prove vital for 
understanding which residents are receiving psychoactive prescriptions and how they are 
responding to treatment when linked with other databases.      
Finally, seniors with missing or unusable data important to the study had to be 
excluded from the analysis.  An example of this would be a home address given as being 
outside of Newfoundland and Labrador for a senior.   The address on file may have been 
a previous home address for the resident or the address of their primary contact.  
Residents in long-term care who remained out of facilities for greater than one week 
between stays were also removed from the analysis.   
 
 
4.6 CHALLENGES AND BARRIERS TO CHANGE   
 When compared to the Canadian average, the province of Newfoundland and 
Labrador has the highest prevalence of seniors aged 65 and over.  In 2013, the treatment 
of seniors over 65 in Canada constituted 44% of healthcare spending (CMA, 2013).  
Given that Newfoundland and Labrador has the highest prevalence of seniors in the 
country, one would expect the burden put on our provincial healthcare system to be 
significant.  
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The Canadian Agency for Drugs and Technologies in Healthcare (CADTH) 
released a document in 2014 comparing policies each province had in place to monitor 
drug use at the provincial level.  Newfoundland and Labrador at the time, was one of 
three provinces that did not have a prescription monitoring program.  The situation was 
only remedied in May of 2016 with the introduction of a province wide system that 
allows pharmacist to monitor all prescriptions (including benzodiazepines and 
antipsychotics).   If a patient is filling multiple prescriptions at different pharmacies 
and/or from different doctors, this information will appear on the system.   
Another challenge is the long wait times for patients to see a specialist who can 
appropriately prescribe psychoactive medications.  As an example, the Newfoundland and 
Labrador Medical Association (NLMA, 2011) states that the average wait time in the 
province for a psychiatrist after referral from a family physician is 30 weeks, the second 
highest out of all provinces.  Over 30% of patients will wait more than a year to be seen.  
In 2015, Newfoundland and Labrador was one of only two provinces in Canada (the other 
being Prince Edward Island) that had no board certified geriatricians practicing (CMA, 
2015).  This situation has only recently been remedied.  The prescription of psychoactive 
medications such as benzodiazepines and antipsychotics require a thorough interview 
process and significant time spent with the patient to find the correct drug and dose.  
While it in unnecessary for all seniors to be managed by a geriatrician, complicated cases 
would preferably be referred to them.   This would help mitigate the problem that the fast-
paced and stressful nature of a (usually privately owned) family practice is not set up to 
handle the complex needs of some seniors despite the physician’s best efforts.   
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4.7 IMPACT OF STUDY AND FURTHER RESEARCH 
This research into the utilization of benzodiazepines and antipsychotics in 
Newfoundland and Labrador provided an in-depth examination into aspects of 
prevalence, rate, and volume as well as geography.  The level of analysis is valuable 
because it allows comparison of rural versus urban areas as well as a more in-depth view 
of regional health authorities than has been previously available.  Further research should 
be conducted that connects diagnosis and outcomes data with prescribing data.  This 
would highlight any possible connections between diagnosis of a condition, severity of 
outcome, and the type of drug which was prescribed for the condition in terms of rate and 
volume of the dose.  In addition, having physician prescribing information would enable 
the researcher to explore any potential patterns in prescribing for individual physicians.  
An extension of this work to incorporate data for all seniors in the province would be a 
logical next step using the already existing pharmacy network.   This would provide a 
more comprehensive view of the utilization patterns of benzodiazepines and 
antipsychotics in Newfoundland and Labrador.   
 Future research into the utilization of benzodiazepines and antipsychotics should 
consider the use of quasi-experimental studies such as interrupted time-series analysis or 
cohort studies.  This would be done in order to examine the programs already initiated 
within Newfoundland and Labrador to evaluate their effectiveness.  Some interesting 
examples of initiatives currently in place include the de-prescribing program set up by the 
medication therapy services (MTS) clinic at Memorial University.  This campaign aims to 
help patients discontinue medications (including benzodiazepines and antipsychotics) 
which they no longer need or may even be doing them harm (School of Pharmacy, 2017). 
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Additionally, the Central and Western Health RHAs through the Canadian 
Foundation for Healthcare Improvement (CFHI) initiated a de-prescribing program aimed 
exclusively at the discontinuation of antipsychotic prescriptions for residents in long-term 
care settings in 2015.  This initiative has now spread province wide with the other two 
health authorities taking part.   
 
 
4.8 RECOMMENDATIONS FOR POLICY MAKERS AND PRACTIONERS 
During the course of this research, several issues became apparent.  Some of these 
relate to the data available for analysis, while others became obvious as results of the 
analysis were revealed.  The following are some of the recommendations that emerged 
from this work. 
These studies on the use of benzodiazepines and antipsychotics relied on 
secondary data compiled for primarily administrative purposes.  While these data served 
the research reasonably well, consideration should be given to compiling and managing a 
database that more directly addresses research needs and serves policy formulation.  
Consideration should also be given to the value of using quasi-experimental studies as 
part of future research initiatives.   
With the recent electronic connection of pharmacies in the province (May 2016), 
more data became available for future research analysis.  If these data are to be utilized to 
their full potential, consideration should be given to devoting more resources, both human 
and electronic, for this purpose. 
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Guidelines such as those advised by the WHO (1996) and followed to various 
degrees by some provincial governments should be studied for potential adoption in this 
province.   These guidelines include, for example, the need of continuing education for 
clinicians, particularly as it relates to important diagnostic information and appropriate 
medication prescription. 
As part of the Choosing Wisely initiative the document, When Psychosis Isn’t the 
Diagnosis, was published in July 2017 (Bueckert et al., 2017).  Already health authorities 
and individual facilities in Newfoundland and Labrador have begun to implement some of 
the recommendations contained in the document.  Serious consideration should be given 
to the full discussion and recommendations contained in the publication.  Provincial 
policies should include the full adoption of these recommendations province wide. 
 
 
4.9 CONCLUSION 
The main objective of this research was to measure variation in the utilization of 
benzodiazepines and antipsychotics in Newfoundland and Labrador over time and across 
geographic and administrative areas.   
Results indicated that the prevalence and rate of prescriptions for both 
benzodiazepines and antipsychotics remained stable over the duration of the study.   It 
was also found that the prevalence and rate of prescriptions for both benzodiazepines and 
antipsychotics were significantly influenced by geography in both the community and 
long-term care settings.  Comparable studies from other parts of North America reached 
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similar conclusions about antipsychotics but the distribution patterns of benzodiazepine 
prescriptions in this province were different from other regions studied.      
The results of the research also show the prevalence for benzodiazepine 
prescriptions to seniors in Newfoundland and Labrador communities being similar to the 
rest of Canada (CIHI, 2012).  However, the prevalence of antipsychotic prescriptions to 
residents in Newfoundland and Labrador long-term care facilities was higher than the 
Canadian average (CIHI, 2016).  With the data currently available to us it is not possible 
to tell whether or not the prevalence of these prescriptions is appropriate.  Further study is 
required that specifically includes diagnosis and severity of condition in order to gain a 
better understanding of appropriate prescribing practices for seniors.   
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Appendix 1.1: Prevalence of Individual Benzodiazepine Agents for Seniors in the 
Community 
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Appendix 1.2: Volume of Individual Benzodiazepine Agents for Seniors in the 
Community in DDDs/1,000 People/Day 
 
 
 
  
 118 
 
Appendix 1.3: Prevalence of Individual Antipsychotic Agents for Seniors in the 
Community 
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Appendix 1.4: Volume of Individual Antipsychotic Agents for Seniors in the Community 
in DDDs/1,000 People/Day 
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Appendix 1.5: Prevalence of Individual Benzodiazepine Agents for Seniors in Long-Term 
Care 
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Appendix 1.6: Volume of Individual Benzodiazepine Agents for Seniors in Long-Term 
Care in DDDs/1,000 People/Day 
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Appendix 1.7: Prevalence of Individual Antipsychotic Agents for Seniors in Long-Term 
Care 
 
 
  
 123 
 
Appendix 1.8: Volume of Individual Antipsychotic Agents for Seniors in Long-Term 
Care in DDDs/1,000 People/Day 
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Appendix 2.1:  Average Days’ Supply for Benzodiazepine Prescriptions in the 
Community 
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Appendix 2.2:  Average Days’ Supply for Antipsychotic Prescriptions in the Community 
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Appendix 2.3:  Average Days’ Supply for Benzodiazepine Prescriptions in Long-Term 
Care 
 
  
 127 
 
Appendix 2.4:    Days’ Supply for Antipsychotic Prescriptions in Long-Term Care 
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Appendix 3.1: Benzodiazepine prescriptions filled in the community by individual agent 
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Appendix 3.2: Antipsychotic prescriptions filled in the community by individual agent 
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Appendix 3.3: Benzodiazepine prescriptions filled in long-term care by individual agent 
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Appendix 3.4: Antipsychotic prescriptions filled in long-term care by individual agent 
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Appendix 4.1: Anatomical Therapeutic Chemical (ATC) codes for all benzodiazepine 
agents 
 
 
  
 Drug Class  Sub Class Agent ATC Code 
    
Benzodiazepines    
 Anticonvulsants Clonazepam N03AE01 
    
 Anxiolytics Diazepam N05BA01 
  Chlordiazepoxide N05BA02 
  Oxazepam N05BA04 
  Potassium Clorazepate N05BA05 
  Lorazepam N05BA06 
  Bromazepam N05BA08 
  Clobazam N05BA09 
  Alprazolam N05BA12 
    
 Sedative/Hypnotics Flurazepam N05CD01 
  Nitrazepam N05CD02 
  Triazolam N05CD05 
  Temazepam N05CD07 
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Appendix 4.2: Anatomical Therapeutic Chemical (ATC) Codes for all antipsychotic 
agents 
 
 
 
 
 
 
 
 Drug Class  Sub Class Agent ATC Code 
    
Antipsychotics      
 Typical Chlorpromazine  N05AA01 
  Levomepromazine  N05AA02 
  Perphenazine  N05AB03 
  Prochlorperazine  N05AB04 
  Trifluoperazine  N05AB06 
  Periciazine  N05AC01 
  Haloperidol  N05AD01 
  Flupentixol  N05AF01 
  Zuclopenthixol  N05AF05 
    
 Atypical Ziprasidone  N05AE04 
  Clozapine  N05AH02 
  Olanzapine  N05AH03 
  Quetiapine  N05AH04 
  Risperidone  N05AX08 
  Aripiprazole  N05AX12 
